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1. Introduction 
 
Porcine Reproductive and Respiratory Syndrome (PRRS) is a virus induced 
infectious disease of pigs. It is also known as “Mystery Swine Disease” or 
“seuchenhafter Spätabort der Schweine”. The virus belongs to the family of 
Arteriviridae from the order Nidovirales and is a small, enveloped positive-stranded 
RNA virus (Benfield et al., 1992; Conzelmann et al., 1993; Meulenberg et al., 1993; 
Zimmerman et al., 2012).  
For the first time PRRS attracted attention in U.S. swine herds in the late 1980s and 
occurred in Europe in 1990 (Lindhaus and Lindhaus, 1991; Zimmerman et al., 2012). 
The causative agent was first isolated in the Netherlands in 1991 and designated 
Lelystad virus (Wensvoort et al., 1992b; Wensvoort et al., 1991).  
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) causes 
reproductive failure in sows leading to late-term abortions and is responsible for 
respiratory tract diseases in fattening pigs followed by a reduced average daily gain 
(Christianson et al., 1992; Lindhaus and Lindhaus, 1991; Terpstra et al., 1991; 
Zimmerman et al., 2012). Thus, it is a significant cause for economic losses 
(Holtkamp et al., 2013; Neumann et al., 2005). Complications by secondary bacterial 
infections (Drew, 2000; Zimmerman et al., 2012) lead to increased antibiotic 
treatments.  
Vaccination is one of the most important measures to prevent PRRSV infection or its 
consequences (Alexopoulos et al., 2005; Mengeling et al., 1999; Zuckermann et al., 
2007). Several commercial attenuated and inactivated vaccines are currently in use. 
However, efficacy of vaccination may be affected by the composition of the vaccine 
(Geldhof et al., 2012) or by genetic diversity among PRRSV field isolates (Labarque 
et al., 2004). Thanawongnuwech and Suradhat (2010) doubted effectiveness of 
currently available vaccines. Geldhof et al. (2012) mentioned the present demand for 
safe and more effective vaccines that induce protection against emerging virus 
variants. They assessed efficacy of different experimental and commercial PRRSV 
vaccines and gained deviating results for the vaccines regarding shortening of 
viremia.  
The aim of several studies concerning PRRSV was and still is to find an acceptable 
possibility for prevention or at least control of PRRS. Molina et al. (2008) concluded 
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that current diagnostic tests are not able to determine the stage of PRRSV infection 
which is a big obstacle to the prevention and control of PRRS.  
The Polymerase chain reaction (PCR) for the detection of virus genome and the 
detection of PRRSV-specific antibodies by an Enzyme-linked immunosorbent assay 
(ELISA) are regularly used in routine diagnosis after vaccination. However, these 
diagnostic tests do not control the success of vaccination. Antibodies detected with a 
commercial ELISA are not protective against PRRSV because they are not 
neutralising. This ELISA detects antibodies directed against the nucleoprotein. 
Neutralising antibodies are directed against epitopes on envelope glycoproteins (GP) 
of the virus (Cancel-Tirado et al., 2004). Furthermore, except for the detection of 
vaccine virus, positive PCR results in vaccinated stocks indicate the failure of 
vaccination or the infection with a heterologous virus. Therefore, these diagnostic 
tests (PCR and ELISA) do not predict the success of vaccination.  
An indicator for success of vaccination is the formation of a protective immune 
response. By measuring parameters of a protective immune response, i.e. 
neutralising antibodies or interferon-(IFN-)-γ, vaccine management might be 
optimised and failure of vaccination might be avoided.  
The present study was created to establish a simple, robust and cost-effective IFN-γ-
recall assay (RA) for PRRSV diagnostics. The objective of this study was to assess 
IFN-γ-response in order to predict immune protection after vaccination. Thus, it 
should be possible, with the aid of SNT and IFN-γ-RA, to assess PRRSV herd 
immunity and recognise gaps in immunity earlier. 
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2. Literature 
 
PRRSV does not represent a uniform virus. Several strains of PRRSV exist. Not only 
the European (EU, genotype 1) and North American (US, genotype 2) PRRSV 
isolates are different to each other (Albina, 1997; Nelson et al., 1993; Wensvoort et 
al., 1992a). Also within the EU- or US-genotypes genetic and antigenic differences 
exist (Forsberg et al., 2002; Kapur et al., 1996; Oleksiewicz et al., 2000; Wensvoort 
et al., 1992a).  
These genetic and antigenic differences affect immune response against PRRSV. 
Infection results in a protective immune response against a re-infection with the 
homologous virus strain (Ohlinger et al., 1991). It develops within 60 days post 
infection (p.i.) and lasts for a minimum of 600 days (Lager et al., 1999, Lager et al., 
1997a, Lager et al., 1997b). Contrary, a protective immunity against a heterologous 
virus strain is incomplete (Labarque et al., 2004; Lager et al., 1999; Mengeling et al., 
1999). Furthermore, it does not last as long as homologous protection (Lager et al., 
1999). On the basis of a cell-mediated immune response, Zuckermann et al. (2007) 
found that modified live virus (MLV) vaccines established a protective immunity 
against a challenge with a PRRSV strain that has a homology of 93% to the vaccine 
virus. In contrast, a killed vaccine virus did not protect against a challenge virus strain 
with 99% homology to the vaccine virus.  
PRRSV proteins are encoded by eight open reading frames (ORF’s), ORF1a and 1b 
encoding the RNA polymerase, ORF 2-4 encoding the minor membrane associated 
proteins and ORF5, 6 and 7 encoding GP5, the non-glycosylated membrane protein 
and the non-glycosylated nucleocapsid protein (Meulenberg et al., 1993; Meulenberg 
et al., 1995). GP5 and the nucleoprotein as well as the non-glycosylated membrane 
protein belong to the major structural and immunogenic proteins of PRRSV. 
Both humoral and cellular immunity are important for PRRSV immunity. The 
development of ELISA antibodies and neutralising antibodies as well as IFN-γ- 
producing cells over time was described by Lopez and Osorio (2004).  
Infection with virulent PRRSV or immunisation with a PRRS-MLV-vaccine induces an 
early increase of non-neutralising antibodies within two weeks (Díaz et al., 2005; 
Nelson et al., 1994; Yoon et al., 1995). Such ELISA antibodies reach their maximum 
within one to two months and begin to decline after three months (Molitor et al., 1997; 
Yoon et al., 1995). Non-neutralising antibodies are directed against the nucleocapsid 
Literature  4 
 
protein (Cancel-Tirado et al., 2004) and against one of two epitopes on the PRRSV 
GP5: epitope A, an immunodominant, non-neutralising determinant (Gonin et al., 
1999; Ostrowski et al., 2002). Epitope B, a neutralising determinant, is a target for VN 
antibodies (Gonin et al., 1999; Ostrowski et al., 2002).   
Virus neutralising (VN) antibodies appear coincidently with the decline of non-
neutralising antibodies (Meier et al., 2003; Shibata et al., 2000). VN antibodies are 
detected within four to eight weeks by Molitor et al. (1997) and Díaz et al. (2005) with 
the highest level at 12 weeks p.i. Osorio et al. (2002) found that VN antibodies are 
protective against subsequent PRRSV infections. Passive transfer of VN antibodies 
protects against an infection with a homologous virus strain (Osorio et al., 2002). 
Glycosylation of GP5, as it can be found in wild type (wt) PRRSV, inhibits the 
induction of VN antibodies because glycans mask the neutralising epitope on GP5 
(Ansari et al., 2006). Current PRRSV isolates showed additional glycosylation sites 
compared to early virus strains (Pesch et al., 2005). In vaccines the removal of 
glycans can improve VN antibodies not only against the homologous vaccine virus 
but also against wt PRRSV (Ansari et al., 2006). Böttcher et al. (accepted) assessed 
the level of neutralising antibodies against the EU- and US-vaccine virus and 
compared it with detection of PRRSV by PCR in the group of weaned piglets.  The 
highest level of EU-SNT-titers was observed in EU-vaccinated sows without 
concurrent circulation of PRRSV-EU in weaned piglets. In contrast, detection of 
PRRSV-EU coincided with a significantly lower level of EU-SNT-titers in sows. 
Moreover, sows of 1./2. parity had significantly lower SNT-titers compared to sows of 
higher parity in these herds.  
Virus-specific IFN-γ-secreting cells appear from day 14 onwards, plateauing at six 
months post infection (p.i.) or post vaccination (p.v.) (Díaz et al., 2005; Meier et al., 
2003; Ohlinger et al., 1991). Porcine IFN-γ blocks PRRSV replication in 
macrophages by inhibiting the viral RNA synthesis (Bautista and Molitor, 1999; 
Rowland et al., 2001).  
A correlation between protection and IFN-γ-secreting cells was observed by Lowe et 
al. (2005) for infection and by Zuckermann et al. (2007) and Martelli et al. (2009) after 
vaccination. But Meier et al. (2003) hypothesised that differentiation of virus-specific 
T-cells into virus-specific IFN-γ-secreting cells is not adequate after exposure to 
virulent or attenuated PRRS virus.  
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IFN-α (or type I IFN), a cytokine secreted by dendritic cells after virus infection, 
stimulates the differentiation of T-cells into IFN-γ-secreting cells (Cella et al., 2000; 
Kadowaki et al., 2000). Meier et al. (2004) described a three-fold increase of the 
PRRSV specific IFN-γ-response when IFN-α was co-administered at vaccination, but 
PRRSV is able to escape the immune response. Five non-structural proteins (NSP), 
NSP1α, NSP1β, NSP2, NSP4 and NSP11, inhibit IFN-α production (Beura et al., 
2010; Royaee et al., 2004). As a consequence, IFN-γ-secreting cells are reduced. 
Nevertheless, even at low level, IFN-γ might promote the differentiation of naive T-
cells into virus-specific IFN-γ-secreting cells leading to a gradual increase in the IFN-
γ-response (Meier et al., 2003). Contrary, Sipos et al. (2003) did not detect changes 
in IFN-γ after the pigs were exposed to PRRSV. This investigation may be an 
indicator for the variability of IFN-γ-responses of pigs against PRRSV.  
Moreover, PRRSV isolates induce secretion of Interleukin-6 (IL-6) and IL-10 early 
after infection (Royaee et al., 2004; Zuckermann et al., 2007). IL-6 produced by 
antigen presenting cells (APC) was found to promote the differentiation of activated 
B-cells into plasma cells secreting antibodies on the one hand and to inhibit IFN-γ-
production on the other hand (Diehl and Rincón, 2002). This situation (type I IFN↓, IL-
6↑, IL-10↑) might favour the formation of antibodies (Royaee et al., 2004) and might 
delay the cellular immune response (Meier et al., 2003). Charerntantanakul et al. 
(2006) reported reduced IFN-γ-expression in T-cells cultured with virulent PRRSV-
infected monocytes. This suppressive activity seems to be associated with virulence 
as it was absent after exposure to attenuated vaccine virus (Charerntantanakul et al., 
2006). As GP5 of PRRSV was found to be a relevant factor for activating humoral 
immunity, it was also examined for its ability to stimulate IFN-γ-secreting cells.  
Using the IFN-γ-ELISpot assay, Vashisht et al. (2008) identified two T-cell epitopes 
on GP5 of an US-field strain stimulating IFN-γ-production in PBMC. Díaz et al. (2009) 
found T-cell epitopes not only in GP5 of an EU-PRRSV, but also additional 
immunodominant epitopes on nucleocapsid and GP4. Nucleocapsid and GP4 also 
seem to be more immunodominant than GP5 (Díaz et al., 2009). Wang et al. (2011) 
finally investigated the membrane protein of PRRSV for immunodominant epitopes 
and identified T-cell epitopes on some peptides of highly virulent PRRSV isolates.  
The importance of IFN-γ in the course of PRRSV infection became obvious regarding 
the study of Díaz et al. (2005), who found that the last detection of viremia in infected 
pigs corresponded to the appearance of IFN-γ-secreting cells. 
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VN antibodies and IFN-γ-response after in vitro stimulation of PBMC with viral 
antigens are suitable prognostic parameters of immunity for diagnostic tests. How VN 
antibodies or IFN-γ-responses, e.g. after vaccination, can be used to predict 
protection against infection has not been determined yet (Lowe et al., 2005; Lowe et 
al., 2006; Molina et al., 2008; Zuckermann et al., 2007). 
Regarding non-neutralising and VN antibodies as well as IFN-γ-response, 
vaccination policy needs to be combined with monitoring the efficiency of vaccination. 
The assessment of the IFN-γ-response either by IFN-γ-ELISpot or IFN-γ-RA and the 
use of SNT might be appropriate in order to predict protection against and to prevent 
an infection with PRRSV. 
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3. Material and Methods 
 
Information about used materials is given in annex 1. 
 
3.1. Preliminary work 
 
3.1.1. Cell culture 
 
MARC145 cells were used for propagation of vaccine virus. Cells were cultured in 
MEM Earle’s (BIOCHROM AG) supplemented with 10 mM HEPES-Buffer, 1% NEA 
and 1% Pen/Strep (EMEM). Porcine Alveolar Macrophages (PAM) were used for 
propagation of field virus strains. Macrophages were cultured in RPMI 1640 
(BIOCHROM AG) supplemented with 1% NEA, 1% Pen/Strep and 1% L-glutamine 
(RPMI). 
 
3.1.1.1. MARC145 
 
MARC145 cells (Kim et al., 1993) were kindly provided by the Friedrich-Loeffler-
Institute, Riems. The cells were passaged in cell culture vessels with 
EMEM/FCS10% and incubated at 37°C without CO2. Confluent monolayers were 
inoculated with vaccine derived PRRSV. For virus titration and serum neutralisation 
MARC145 cells were seeded on a 96-well microtiter plate at a density of 50.000 
cells/well. The plate was incubated at 37°C and 5% CO2. Two days later, when the 
cell monolayer was confluent, the cells were used for further tests. All in all, the cells 
were used for up to 30 passages for virus propagation. 
 
3.1.1.2. Porcine Alveolar Macrophages (PAM) 
 
PAM (Mengeling et al., 1995; Wensvoort et al., 1991) were harvested from lungs of 
piglets as previously described (Mengeling et al., 1995; Wensvoort et al., 1991; Yoon 
et al., 1992), with some minor modifications of the procedure. Piglets with approx. 20 
kg were obtained from a stock tested free of PRRSV by antibody ELISA, SNT and 
PCR. They tested negative (PCR) for porcine circovirus type 2, swine influenza virus 
and Mycoplasma hyopneumoniae. Lungs were flushed five to ten times with cold 
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(4°C) RPMI 1640 supplemented with 1% Pen/Strep, 1% patricin and 0.04% baytril 
5%. Lavage fluid was filtered through gauze and collected in a sterile vessel of glass 
on ice. Lavage fluid was sedimented at 750 x g for 10 minutes. Pellets of PAM were 
resuspended in 10 ml RPMI/FCS10% for cell counting. Then PAM were sedimented 
once more and resuspended in medium containing 40% RPMI 1640 (including 1% 
NEA and 1% L-glutamine), 50% FCS and 10% DMSO for storage in liquid nitrogen. 
The cell number for freezing was set to a concentration of 1.2x106 cells/ml. Aliquots 
of 1 ml were stored in liquid nitrogen. PAM were examined for sterility on blood agar 
as well as for PRRSV, porcine circovirus type 2, swine influenza virus and 
Mycoplasma hyopneumoniae by PCR.  
For use, PAM were thawed, sedimented by centrifugation and resuspended in 
RPMI/HS10% at a density of 105 cells/ml. After overnight incubation at 37°C and 5% 
CO2, PAM were used for propagation of field virus. 
 
3.1.1.3. Counting of cells 
 
Cell suspension was appropriately diluted with PBS and trypan blue (890 µl PBS, 100 
µl trypan blue, 10 µl cell suspension). A Fuchs-Rosenthal counting chamber was 
used for counting cells and cell numbers per ml were calculated in consideration of 
dimension of the counting chamber and the pre-dilution. 
 
3.1.2. Titration of virus 
 
Virus titers were determined according to Wills et al. (1997) on MARC145 cells for 
vaccine virus and on PAM in case of field virus strains in 96-well microtiter plates. For 
titration, ten log10-dilutions of virus were prepared. In case of vaccine derived 
antigens, 50 µl/well of each virus dilution were inoculated on a monolayer of 
MARC145 cells in six replicates and incubated for 1 hour at 37°C and 5% CO2. Then 
50 µl/well EMEM/FCS10% were added. In case of field virus derived antigens, 10 µl 
of field virus strain dilutions were given in six replicates to 90 µl of PAM in 
RPMI/FCS10% (approx. 10.000 cells/well). Six more wells were filled with medium as 
cell control. After 5-7 days, wells of each microtiter plate were examined for 
cytopathic effect (CPE). The titer of virus was determined according to the method of 
Kaerber (Schmidt & Emmons, 1989): 
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Negative logarithm of TCID50 = x0 – (((Σ%CPE/100) – 0.5) x (log d)) 
 
x0 = logarithm of the highest virus concentration used 
Σ%CPE = sum of % cytopathic effect at each dilution 
log d = logarithm of dilution series (1 in the case of log10-dilution) 
 
3.1.3. Propagation of virus 
 
Vaccine virus was re-isolated from two commercially available vaccines (Ingelvac® 
PRRS MLV, Boehringer, Ingelheim; genotype 2; US vaccine virus strain and 
Porcilis® PRRS, MSD/Intervet, Boxmeer; genotype 1; EU vaccine virus strain) on 
MARC145 cells. Virus was passaged for 12 times. Four field virus strains FI I-IV 
(V2276/I/2012, V1192/2013, V683/2013, V995/2013) were isolated from tissues from 
pigs. Lungs, spleens and afterbirths were homogenized and inoculated to PAM at a 
ratio of one to ten. Cells were observed daily for CPE for up to 7 days after 
inoculation. When CPE was observed, supernatant was used for further passages of 
the virus in PAM (five to six passages).  
The titer and number of passage for seed virus stocks are summarized in Table 1. 
Sequencing of the isolated field virus strains was done by IVD GmbH (Gesellschaft 
für Innovative Veterinärdiagnostik mbH, Hannover). Based on the ORF5 gene the 
isolates FI I, FI II and FI III were compared with the reference strain Lelystad virus. 
The isolate FI IV was compared with the reference strain Lelystad virus by ORF7 
because amplification of ORF5 was not successful for this isolate. The segment of 
ORF7 is shorter than the segment of ORF5 (Fig. 1). The PRRSV nucleotide 
sequences of FI I, FI II, FI III and FI IV shared a homology of 89%, 89%, 87% and 
93% to the PRRSV EU reference strain Lelystad in ORF5 (FI I, FI II, FI III) and ORF7 
(FI IV) respectively. 
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Table 1: Characteristics of seed virus stocks.  
 passage titer 
vaccine virus 
US 12th 107.5/ml 
EU 12th 107.8/ml 
field virus 
FI I 6th 104.13/ml 
FI II 5th 105.1/ml 
FI III 5th 106/ml 
FI IV 5th 105.8/ml 
 
Source: Own presentation 
 
3.1.3.1. Antigen preparations – vaccine derived virus 
 
The value of different PRRSV antigen preparations had to be assessed for IFN-γ-
stimulation. Two vaccine derived virus strains were used. Three antigen preparations 
of US and EU vaccine virus were produced as cell culture supernatants: antigen in 
EMEM/FCS10%, antigen in EMEM w/o FCS and cell-lysates of infected cells in PBS. 
MARC145 cells were rinsed with PBS and inoculated with virus in EMEM w/o FCS. 
Antigen in EMEM/FCS10%: cell culture (30th passage) was inoculated with a 
multiplicity of infection (MOI) of 0.1. After incubation for 1 hour at 37°C and 5% CO2, 
the culture vessel was half filled with EMEM/FCS10%. Cell cultures were incubated 
48 hours (CPE ~ 75%) at 37°C and 5% CO2. 
An uninfected MARC145 cell culture was prepared as control antigen 
(MARC145/FCS). Cells were rinsed with PBS, covered with EMEM w/o FCS for 1 
hour at 37°C and 5% CO2 and then half refilled with EMEM/FCS10%. Uninfected cell 
culture was incubated 48 hours at 37°C and 5% CO2. 
Antigen in EMEM w/o FCS: cell culture (31th passage) was inoculated with a MOI of 
1. After incubation for 1 hour at 37°C and 5% CO2, the culture vessel was half filled 
with EMEM/FCS10%. Six hours later, medium was discarded, cells were rinsed with 
PBS and covered again with EMEM w/o FCS. Cell cultures were incubated additional 
40 hours (CPE ~ 25%) at 37°C and 5% CO2. 
An uninfected MARC145 cell culture was prepared as control antigen (MARC145 w/o 
FCS). Cells were rinsed with PBS, covered with EMEM w/o FCS for 1 hour at 37°C 
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and 5% CO2 and then half refilled with EMEM/FCS10%. Six hours later, medium was 
discarded, cells were rinsed with PBS and covered again with EMEM w/o FCS. 
Uninfected cell culture was incubated additional 40 hours at 37°C and 5% CO2. 
Cellysate-antigen in PBS: cell culture (29th passage) was inoculated with a MOI of 
1. After incubation for 1 hour at 37°C and 5% CO2, the culture vessel was half filled 
with EMEM/FCS10%. Sixteen hours later (beginning CPE), supernatant was 
discarded and the cells were collected in a tenth volume of PBS. 
An uninfected MARC145 cell culture was prepared as control antigen (MARC145). 
Cells were rinsed with PBS, covered with EMEM w/o FCS for 1 hour at 37°C and 5% 
CO2 and then half refilled with EMEM/FCS10%. Sixteen hours later, supernatant was 
discarded and cells were collected in a tenth volume of PBS. 
Next, the cells of the different antigen preparations were lysed by three freeze-thaw 
cycles (-20°C/25°C). Lysate was cleared by centrifugation at 250 x g for 10 minutes. 
Supernatant was aliquoted and stored at -80°C. Antigens and virus titers are 
summarized in Table 2. 
 
3.1.3.2. Antigen preparations – field virus strains 
 
Isolates FI I-IV were used as seed virus. PAM cultures were infected with a MOI of 
0.01. The cell culture medium contained 10% horse serum. After three days, CPE 
was 100%. The remaining cell particles were sedimented by centrifugation at 250 x g 
for 10 minutes. The supernatants were aliquoted and stored at -80°C. The CPE was 
confirmed by indirect immunofluorescence. The field virus antigens used for 
stimulation had titers of 105/ml (FI I), 104.2/ml (FI III) and 104/ml (FI II, FI IV). 
An uninfected PAM cell culture was prepared as control antigen (PAM). The cell 
culture was incubated in RPMI for three days. After one freeze-thaw cycle, remaining 
cell particles were sedimented by centrifugation at 250 x g for 10 minutes. The 
supernatants were aliquoted and stored at -80°C. 
 
3.1.4. Storage of antigens 
 
Aliquots of antigens and control antigens were stored at -80°C and for examination of 
stability at -20°C and +2 - 8°C. The stimulation control was stored at -20°C. 
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Figure 1: Genetic analysis of field isolates – sequence data  
0: reference strain Lelystad, 1: FI I, 2: FI III, 3: FI II, 4: FI IV; a/b: Sequencing of ORF5 (a) or ORF7 (b). 
Source: IVD GmbH 
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Table 2: Antigens and control antigens 
 titer control antigen 
US in EMEM/FCS 107.5/ml MARC145/FCS 
EU in EMEM/FCS 107.8/ml MARC145/FCS 
US in EMEM w/o FCS 106.3/ml MARC145 w/o FCS 
EU in EMEM w/o FCS 106.1/ml MARC145 w/o FCS 
US in PBS 108.6/ml MARC145 
EU in PBS 108.3/ml MARC145 
FI I 105/ml PAM 
FI II 104/ml PAM 
FI III 104.2/ml PAM 
FI IV 104/ml PAM 
 
Source: Own presentation 
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3.2. Detection of antibodies and antigens 
 
3.2.1. Antibody ELISA 
 
A commercial enzyme linked immunosorbent assay (indirect ELISA) was used to 
detect antibodies against PRRSV in serum samples (Herd Chek* PRRS X3, Porcine 
Reproductive and Respiratory Syndrome Virus Antibody Test Kit, IDEXX 
Laboratories). The IDEXX ELISA was performed following the kit instructions. All 
reagents were provided. Diluted serum samples and undiluted positive (PC) and 
negative controls (NC) were added to the wells of the test plate. Test plates were 
coated with recombinant PRRSV antigen (PRRSV capsid protein). Antibodies 
specific for PRRSV bound to the coated antigens during an incubation period of 30 
minutes at room temperature. Unbound material was removed by washing the plate 
five times. An anti-porcine immunoglobulin linked to horseradish peroxidase was 
added, binding to the porcine antibody fixed in the wells. After incubation for 30 
minutes at room temperature and washing the plate five times, TMB substrate was 
added and incubated for 15 minutes at room temperature. The stop solution finished 
the enzymatic reaction. 
Optical density (OD) was measured at 650 nm with a microplate reader for ELISA 
assays (Sunrise™, Tecan Austria GmbH, Grödig). Reactivity of samples was 
calculated with the following formula: 
 
% reactivitysample = ((ODsample – ODNC) / ( ODPC – ODNC) ) * 100 
 
As the positive and negative controls were tested in duplicate, the average value of 
the two measured values for each control was used for calculation. 
Evaluation considered a threshold area of 30-40% reactivity. 
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3.2.2. Serum neutralisation test (SNT) 
 
Titers of VN antibodies were determined by the SNT according to Yoon et al. (1994) 
and modified by Böttcher et al. (2006) against EU and US vaccine virus. A heat-
treatment of sera (water bath, 60°C, 30 minutes) was performed. Vaccine virus was 
diluted to 200 TCID50/50µl in EMEM supplemented with 4% serum from guinea pigs 
as a source of complement. Heat-inactivated sera were diluted 1/2, 1/4 and 1/8 in 
EMEM in an empty 96-well microtiter plate with a final volume of 50 µl/well. 50 µl 
Virus (200 TCID50/50µl) were added. Wells with medium only, a back-titration of 
infectivity and a 1/2-dilution of sera without virus were included as additional controls. 
The plate was incubated for 1 hour at 37°C and 5% CO2. The supernatant of a 
microtiter plate with confluent cells was discarded and 50 µl from each well of the 
pre-incubation plate were transferred. After another incubation (1 hour at 37°C and 
5% CO2), 50 µl/well EMEM/FCS10% were added. The test was incubated for 5-6 
days at 37°C and 5% CO2. Cells were regularly examined for CPE. The serum 
control was checked for cytotoxicity.  
The neutralisation titer of antibodies was calculated by the method of Kaerber 
(Schmidt & Emmons, 1989) and expressed as <2; 2.8; 4; 5.6; 8 and ≥11.2. 
 
3.2.3. Real-time reverse transcriptase polymerase chain reaction (PCR) 
 
PCR was performed to detect and quantify viral RNA in serum. RNA was extracted 
from serum samples with the QIAamp® Viral RNA Mini-Kit (QIAGEN®) following the 
kit instructions. The samples were mixed by pulse-vortexing in a 1.5 ml micro tube. 
The micro tube contained a prepared Buffer AVL-carrier RNA (provided by 
QIAGEN®) and serum. Incubation at room temperature led to viral particle lysis. 
Ethanol was added to the sample. The solution was applied to a QIAamp Mini spin 
column in a 2 ml collection tube (QIAGEN®). By centrifugation, RNA bound to the 
QIAamp membrane. Contaminants were washed away in two steps using two 
different wash buffers (Buffer AW1 by QIAGEN® and Buffer AW2 by QIAGEN®). 
RNA was eluted in a 1.5 ml microcentrifuge tube with RNAse-free buffer (Buffer AVE 
by QIAGEN®). RNA could be used directly for PCR. PCR was carried out with 
VIROTYPE® PRRSV (Real-time Multiplex RT-PCR Test Kit for Detection of EU, NA 
and HP PRRS Viruses, Labor Diagnostik GmbH Leipzig) including enzymes, primers 
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and probes in one mixture (PRRSV-Mix) as well as a positive and a negative control. 
The test kit can be used to detect EU- and US-genotype of PRRSV, a highly 
pathogenic (HP) strain of US-genotype and an amplification- and extraction control 
(mRNA of β-actin housekeeping gene) at the same time. PRRSV-Mix was prepared 
with the RNA elution using Optical Tube Strips (Agilent Technologies). The 
formulation per sample included 80% of PRRSV-Mix and 20% of sample or controls. 
PCR was performed on Stratagene M3005P (Agilent Technologies). The profile of 
temperature and time is shown in table 3. 
Analysis was based on threshold cycle (Ct) determinations using the Mx Pro QPCR 
Software (Agilent Technologies). 
 
Table 3: Temperature profile for PCR 
 time period temperature 
reverse transcriptase 10 min 45°C 
taq polymerase 10 min 95°C 
40 series 
Denaturation 15 sec 95°C 
Annealing 30 sec 55°C 
Measuring   
Elongation 30 sec 72°C 
 
Source: VIROTYPE® PRRSV, Instructions for Use, Labor Diagnostik GmbH Leipzig 
 
3.2.4. Indirect immunofluorescence 
 
Indirect immunofluorescence (IF) was used to confirm virus induced CPE in cell 
cultures. Cells were fixed with acetone on a slide and incubated with an anti-PRRSV 
antibody (BioX Diagnostics, diluted 1:20) for 1 hour in a humid chamber at 37°C. 
Cells were washed three times with PBS (pH 7.4) for 5 minutes. An Fluorescein 
isothiocyanate (FITC) conjugated anti-mouse IgG (Sigma-Aldrich®, diluted 1:250) 
was added.  After another incubation period for 1 hour in a humid chamber at 37°C, 
cells were washed again as described above and were subsequently covered with 
DABCO buffer (PBS and glycerol in equal volumes supplemented with 3.5% DABCO) 
and a coverglass. Cells were examined with a fluorescence microscope (20x 
magnification, Intensilight C-HGFI, Nikon). An uninfected cell culture also was 
prepared for indirect immunofluorescence as negative control. 
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3.3. Detection of IFN-γ 
 
3.3.1. Counting of peripheral blood mononuclear cells (PBMC) 
 
Peripheral blood mononuclear cells (PBMC) were counted (Cell-Dyn 3500, Abbott, 
Illinois). Automated counting was initially confirmed by a Neubauer counting 
chamber.  
 
3.3.2. Stimulation of blood samples with antigens 
 
Stimulation of PBMC in Li-Heparin-stabilized blood was principally performed 
according to Böttcher et al. (2010). Blood samples were stimulated within 8 hours 
after collection. Stimulation was performed in a laminar flow with sterile equipment. 
Viral antigens (US, EU) and control antigen (MARC145) were heat-inactivated in a 
water bath (60°C, 30 minutes). Pokeweed mitogen (Sigma-Aldrich®), activating 
humoral and cellular immune response (Mellstedt, 1975), was used as a stimulation 
control (SC) and thus as a positive control for functionality of PBMC. PBS served as 
a further negative control. US, EU, MARC145 and SC were prediluted to a working 
concentration in PBS. Diluted antigens, control antigen, SC and PBS (each 20 µl) 
were distributed to appropriate wells of a cell-culture microtiter plate. Blood samples 
were thoroughly mixed end-over-end and 280 µl whole blood were distributed to 
appropriate wells with antigens and controls. The microplate was shaked to mix 
antigen and blood. Each blood sample was stimulated in duplicate. Stimulation was 
performed for 16 hours at 37°C and 5% CO2. The next day, plasma was separated 
by centrifugation at 500 x g for 5 minutes and transferred to a storage microtiter plate. 
Plasma was either immediately transferred to the IFN-γ-RA test plate or stored at       
-20°C for later use. 
The following variations of the basic protocol were included: 
Additional controls: control antigen prepared in PBS (MARC145/PBS), EMEM w/o 
FCS and PBS/FCS10% were prepared for stimulation of blood samples in order to 
assess any reactivity against medium components. 
FCS and horse serum (HS): PBS/FCS10%, PBS/FCS1%, PBS/HS10% and 
PBS/HS1% were prepared for stimulation of blood samples in order to assess any 
reactivity against serum components. 
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Field virus and PAM: four field isolates FI I-IV and the PAM control were included 
for stimulation of blood samples. 
 
3.3.3. IFN-γ-recall assay (IFN-γ-RA) 
 
Two porcine IFN-γ kits, test kit A (R&D Systems®) and B (Mabtech), were compared 
regarding user-friendliness, detection limit and costs. Annex 2.1, annex 2.2 and 
annex 3 are summarising the components of the used test kits and their 
implementation. 
Test kit A: a high protein binding ELISA plate (Nunc-Immuno™ Plates, MaxiSorp) 
had to be coated with a monoclonal antibody specific for porcine IFN-γ (mouse anti-
porcine IFN-γ). Mab was diluted in PBS (pH 7.4) to 2 µg/ml. Coating was performed 
overnight at 4°C. The antibody coated microtiter plate was washed three times with 
wash buffer and blocked with Reagent Diluent for 1 hour at room temperature. After 
another three washing procedures the plate was ready for use. 
Upon arrival, the standard was reconstituted in Reagent Diluent to a concentration of 
0.075 µg/ml and stored in aliquots at -20°C until use. Using 2-fold serial dilutions, a 
seven point standard curve with IFN-γ-concentrations ranging from 62.5 to 4000 
pg/ml was performed. Reagent Diluent served as zero negative value. 
Stimulation of blood samples with antigens should result in IFN-γ-production of 
PBMC if PRRSV infection or vaccination had been taken place before. Plasma 
samples were diluted 1:2 in Reagent Diluent. The samples and the undiluted 
standard series were transferred to the test plate. IFN-γ bound to the immobilized 
antibody on the microtiter plate within an incubation period of 2 hours at room 
temperature. The biotinylated polyclonal antibody, diluted in Reagent Diluent with 2% 
heat inactivated normal goat serum (NGS) to 0.4 µg/ml (incubation period 2 hours), 
and Streptavidin-Horseradish Peroxidase, diluted in Reagent Diluent 1:200 
(incubation period 20 minutes), were added. Every incubation period was followed by 
three washing steps to remove unbound material. Tetramethylbenzidine (CHECKIT* 
TMB substrate, Idexx Laboratories) was used as substrate solution and enzymatic 
reaction was stopped after 20 minutes with an appropriate stop solution (CHECKIT* 
stop solution TMB, Idexx Laboratories). 
Test kit B: a high protein binding ELISA plate (Nunc-Immuno™ Plates, MaxiSorp) 
had to be coated with a monoclonal antibody specific for porcine IFN-γ (mouse anti-
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porcine IFN-γ). Mab was diluted in PBS (pH 7.4) to 2 µg/ml. Coating was performed 
overnight at 4°C. The antibody coated microtiter plate was washed twice with PBS 
and blocked with the incubation buffer for 1 hour at room temperature. After another 
five washing procedures the plate was ready for use. 
Upon arrival, the standard was reconstituted in PBS with 0.1% BSA to a 
concentration of 0.5 µg/ml and stored in aliquots at -20°C until use. 10, 100 and 1000 
pg/ml and incubation buffer (zero value) served as standard curve.  
Plasma samples were diluted 1:2 in incubation buffer. The samples and the undiluted 
standard series were transferred to the test plate. IFN-γ bound to the immobilized 
antibody on the microtiter plate within an incubation period of 2 hours at room 
temperature. The biotinylated monoclonal antibody, diluted in incubation buffer to 0.5 
µg/ml (incubation period 1 hour), and Streptavidin-Horseradish Peroxidase, diluted in 
incubation buffer 1:1000 (incubation period 1 hour), were added. Every incubation 
period was followed by five washing steps to remove unbound material. TMB 
substrate (CHECKIT* TMB substrate, Idexx Laboratories) was used as substrate 
solution and enzymatic reaction was stopped after 10 minutes with an appropriate 
stop solution (CHECKIT* stop solution TMB, Idexx Laboratories). 
Measurement: OD’s were measured at 450 nm with a photometer for ELISA assays 
(Sunrise™, Tecan Austria GmbH).  
Calculation: plasma samples were tested in duplicates. The two values (OD) were 
averaged. Reactivity to PBS control was subtracted from that to SC (ODSC-ODPBS) 
and control antigen (ODMARC145-ODPBS). Thus, specific reactivity to SC and MARC145 
could be examined. PBS control and the control antigen were used as negative 
controls. Reactions occurring in these controls had to be differentiated from specific 
reactivity to US- and EU-antigen. To get the specific reactivity to these two antigens, 
OD of MARC145 (before subtracting PBS) was subtracted from OD to US- and EU-
antigens (ODus-ODMARC145 and ODEU-ODMARC145) respectively. Specific (US, EU) and 
control antigens (PBS, MARC145) were expressed as a percentage of (ODSC-
ODPBS).  
The standards were tested in duplicate, which were averaged and corrected by 
subtraction of zero value (standard diluent). The standard curve was controlled for 
regularity. If needed, ODs of the standard curve were used to calculate the amount of 
IFN-γ produced by PBMC of the samples.  
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3.3.4. IFN-γ-ELISpot 
 
An IFN-γ-ELISpot (ELISpot for Porcine IFN-γ, R&D Systems) was performed 
according to the kit instructions. All reagents were provided with the test kit. 
Purification of PBMC: using Ficoll-Paque™ PLUS (GE Healthcare), PBMC were 
separated according to the manufacturer’s instructions. Li-Heparin-stabilized blood 
samples were mixed with PBS in equal volumes. Four ml of diluted blood sample 
were carefully layered on 3 ml Ficoll-Paque™ PLUS. Centrifugation at 400 x g for 30 
minutes at 20°C led to separation of blood cells. The PBMC layer was separated and 
suspended in PBS. Two additional centrifugation steps at 100 x g for 10 minutes 
each removed remaining platelets, Ficoll-Paque™ PLUS and plasma. PBMC then 
were resuspended in RPMI and used for stimulation. 
Preparation of the ELISpot plate: the PVDF-backed microplate coated with a Mab 
specific for porcine IFN-γ was covered with RPMI/HS10%, and incubated for 20 
minutes at room temperature. The culture medium was aspirated and the plate was 
ready for immediately use. 
Stimulation: cell suspensions including the stimulatory agents were transferred to 
the test plate. 2.5x105 PBMC/well were stimulated with the same antigens and 
dilutions used for the IFN-γ-RA. The plate was incubated at 37°C and 5% CO2 for 20 
to 24 hours. 
IFN-γ-ELISpot: cell suspension was discarded and the plate was washed four times 
with the provided wash buffer concentrate diluted in distilled water. The detection 
antibody, a biotinylated polyclonal antibody for porcine IFN-γ, diluted in the provided 
Dilution Buffer 1 (incubation period overnight at 2-8°C), and the Streptavidin-Alkaline 
Phosphatase, diluted in the provided Dilution Buffer 2 (incubation period 2 hours at 
room temperature), were added. Every incubation period was followed by four 
washing steps. The provided BCIP/NBT Chromogen was used as substrate solution 
(incubation period 1 hour at room temperature). Colour development was stopped by 
washing with distilled water. The plate was left aside to air dry. Spots were counted 
by an ELISpot reader (AID iSpot FluoroSpot Reader System, AID Autoimmun 
Diagnostika GmbH). 
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3.4. Statistical analysis 
 
Statistical analysis was done with MedCalc® version 9.5.2.0. (MedCalc Software). 
Normal distribution of results was checked with the Kolmogorov-Smirnov test 
(p>0.05). According to the result, an ANOVA or the Kruskal-Wallis test were used for 
further analysis. Further tests were mentioned if used. Box and whisker plots were 
mainly used for presentation of results. 
 
3.5. Animals and samples 
 
Examinations were carried out with blood samples collected from non-
vaccinated/non- infected, non-vaccinated/infected, US-vaccinated and EU-vaccinated 
sows. No animal experiment was done. Blood samples were taken in the course of 
routine diagnosis in stocks. Blood samples for the IFN-γ-RA using Li-Heparin as an 
anticoagulant and serum samples for SNT, PCR and antibody ELISA were collected. 
Blood samples were taken from V. jugularis. In total, 458 pigs of 49 stocks were 
tested. The sampling plan compromised ten blood samples per herd randomly 
collected from sows with different numbers of parity. Thirty-two blood samples were 
excluded from testing because the lack of or coagulated sample material. 
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4. Results 
 
4.1. Analysis of IFN-γ-standards of two test kits 
 
ODs for different concentrations of IFN-γ standards were examined. Kits from two 
manufacturers (A and B) were included (Fig. 2a-d). The minimum of detectable IFN-
γ-standard as well as interplate and interday variation of standard curves were 
analysed. For the reason of comparability of kit A and B a maximum standard of 1000 
pg/ml was used in the upcoming graphical representations. 
According to the manufacturer’s instructions, the standard of kit A was log2-diluted 
from 4000 to 62.5 pg/ml, whereas in kit B it was log10-diluted and ranged from 1000 
to 10 pg/ml. A similar OD range at low IFN-γ-concentrations was detected in both 
kits. Regarding interplate and interday variation, kit B showed a greater interday 
variation than kit A (F-test for standard with IFN-γ-concentration of 1000 pg/ml, 
P<0.05). 
Kit A IFN-γ-standard was tested at concentrations of 10, 100 and 1000 pg/ml in order 
to compare the detectability (Fig. 3). Kit A was unable to discriminate the lowest 
concentration (10 pg/ml) from the negative standard. Thus a higher detectability was 
observed for Kit B. 
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Figure 2: Optical densities of different IFN-γ-standard concentrations.  
Source: Own presentation  
Interplate (left) and interday (right) variation for test kit A (a,b) and B (c,d) are shown. Standards 
provided with the respective kit were used at prescribed concentrations. For interplate and interday 
variation, six and ten tests per concentration were used. 
 
 
 
Figure 3: Optical densities of kit A IFN-γ-standard in kit B IFN-γ-standard concentrations.  
Source: Own presentation 
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4.2. Titration of stimulation control 
 
SC was implemented to confirm the viability and ability of PBMC to produce IFN-γ 
and to serve as a positive control to express the pathogen-specific IFN-γ-response as 
percent. SC-IFN-γ-reactivity should be as close as possible to that of positive blood 
samples to pathogen-specific antigens. If IFN-γ-reactivity to SC is too strong, the 
reaction has to be stopped before a sufficient reactivity of blood samples to 
pathogen-specific antigens developed. In order to assess the optimal concentration 
of SC, blood samples of 30 sows from three different stocks were stimulated with SC 
at 0.6, 0.3 and 0.17 µg/ml (Fig. 4). A concentration of 0.6 µg/ml resulted in IFN-γ-
reactivity well distributed in the measuring range of the photometer. Twenty-three 
percent (kit A) and 10% (kit B) of the samples showed a reactivity below 0.4 (OD, 
validation criterion), whereas at a concentration of 0.3 µg/ml, 73% (kit A) and 60% (kit 
B) of the samples failed the criterion. Kit B showed a significantly stronger reactivity 
at 0.6 µg/ml (ANOVA, P<0.05), however, a significantly higher OD was observed for 
PBS, too. 37% of samples in kit B and only 7% in kit A failed the validation criterion 
ODPBS<0.2. 
 
 
 
Figure 4: Quantification of IFN-γ after stimulation of Li-heparin-stabilized blood samples with different 
concentrations of pokeweed mitogen (SC).  
Source: Own presentation 
Kit A and B (nstock=3, nsow=30) were used. Stimulation with PBS served as a blank. 
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4.3. Reactivity against MARC145/FCS (control antigen) 
 
Aside from an unspecific IFN-γ-reactivity in unstimulated blood samples (PBS) in kit 
B, an additional unspecific IFN-γ-reactivity against the control antigen 
(MARC145/FCS) was observed in both kits (Fig. 5). Blood samples of 20 sows from 
four different stocks were examined for reactivity against MARC145/FCS. The 
validation criterion ODPBS <0.2 was not applied. Differences for MARC145/FCS 
between kits A and B were not significant (ANOVA, P>0.05).  
To analyse the components of the control antigen for unspecific IFN-γ-reactivity, 
blood samples from 20 sows from two different stocks were examined for reactivity to 
MARC145/FCS, MARC145/PBS, PBS/FCS and EMEM w/o FCS (Fig. 6). FCS was 
responsible for the unspecific IFN-γ-response. This analysis was only performed in kit 
B.  
In a second series of tests FCS was replaced by HS. Twenty blood samples of sows 
from two different stocks were examined (Fig. 7). Unspecificity was caused by FCS 
but was not detected for HS, however, differences were not significant (ANOVA, 
P>0.05)     
 
 
 
 
 
Figure 5: Unspecific reactivity in IFN-γ-RA (kit A and B).  
Source: Own presentation 
Stimulation of Li-heparin-stabilized blood samples with PBS and MARC145/FCS (nstock=4, nsow=20). 
The IFN-γ-reactivity was expressed as a percentage of SC and the maximum reactivity was restricted 
to 100%. %ODPBS and %ODMARC145/FCS were multiplied by -1. The validation criterion ODPBS <0.2 was 
not applied. 
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Figure 6: Analysis of MARC145/FCS components for unspecific IFN-γ-reactivity in test kit B (nstock=2, 
nsow=20).  
Source: Own presentation 
The IFN-γ-reactivity was expressed as a percentage of SC and the maximum reactivity was restricted 
to 100%. Values of negative controls were multiplied by -1. The validation criterion ODPBS <0.2 was not 
applied. PBS/FCS = PBS supplemented with 10% FCS, MARC145/PBS = MARC145 prepared in PBS 
instead of EMEM/FCS10%. 
 
 
 
 
 
Figure 7: Analysis of HS as a substitute for FCS in test kit B (nstock=2, nsow=20).  
Source: Own presentation 
IFN-γ-reactivity was expressed as a percentage of SC and the maximum reactivity was restricted to 
100%. Values of negative controls were multiplied by -1. The validation criterion ODPBS <0.2 was not 
applied. PBS/FCS10% = PBS supplemented with 10%FCS; PBS/FCS1% = PBS supplemented with 
1%FCS; PBS/HS10% = PBS supplemented with 10%HS; PBS/HS1% = PBS supplemented with 
1%HS. 
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4.4. IFN-γ-reactivity against PRRSV-specific and control antigens 
 
Subsequent experiments were performed with kit A because of a lower variation of 
interday variance and less frequently observed IFN-γ-responses in unstimulated 
blood samples (PBS). In order to circumvent the use of FCS, cell lysates of PRRSV-
infected and non-infected MARC145-cells had been produced. The optimal dilution of 
these antigens for stimulation of blood samples was determined in PRRSV-US-
vaccinated (Fig. 8a) and PRRSV-EU-vaccinated (Fig. 8b) stocks. Blood samples from 
nine US-vaccinated and eight EU-vaccinated sows were stimulated with final antigen 
dilutions of 1:150, 1:750 and 1:1500 (pre-dilutions 1:10, 1:50 and 1:100). In 
particular, the dilution of US-antigen was investigated with blood samples of US-
vaccinated animals and the dilution of EU-antigen with blood samples of EU-
vaccinated animals. A remarkably specific IFN-γ-response was observed for EU- and 
US-antigens in EU- and US-vaccinated herds, respectively. However, no significant 
differences were observed between the dilutions (ANOVA, P>0.05), although a 
tendency of a reduced reactivity upon dilution was evident at least for the US-
antigen. Therefore in the following experiments two dilutions of the antigens (1/150 
and 1/750) were applied.    
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Figure 8: Effect of PRRSV-EU- and -US-antigen dilution on IFN-γ-reactivity.  
Source: Own presentation 
Li-heparin-stabilized blood samples from sows originating from US- (a, nstock=2, nsow=9) and EU-
vaccinated (b, nstock=1, nsow=8) herds were stimulated with dilutions of antigens. IFN-γ-reactivity was 
expressed as a percentage of SC and the maximum reactivity was restricted to 100%. %ODPBS and 
%ODMARC145 were multiplied by -1. 
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4.5. IFN-γ-profiles of sows 
 
In order to determine the feasibilty of the PRRSV-IFN-γ-RA sows from herds with a 
different history of PRRSV-infection and vaccination were tested. Therefore, blood 
samples from non-vaccinated/non-infected, non-vaccinated/infected, US-vaccinated 
and EU-vaccinated sows were tested. As indirectly indicated by the litter number 
different age groups of sows were considered.  
A total of 261 sows from 27 stocks were examined. Validation criteria led to the 
exclusion of 13% of samples (17 samples with ODSC <0.4 and 17 samples with 
ODPBS ≥0.2). Annex 4 gives an overview of the analysed and invalid samples. 
An estimate on specificity of the IFN-γ-test was assessed by testing non-
vaccinated/non-infected stocks (Fig. 9a). Blood samples from 28 sows from three 
stocks were investigated and 7% (two samples from one stock) of the samples were 
invalid because ODSC <0.4. A slight reactivity was observed against MARC145 at a 
dilution of 1:150. The maximum reactivity for US- (1:150) and EU-antigen (1:150) was 
12.6% and 8%, respectively.    
Thirty sows from three non-vaccinated/infected stocks were studied for their IFN-γ-
reactivity (Fig. 9b). 20% of the samples failed the validation criteria. Reactivity against 
MARC145 was comparable to those in Fig. 9a. A stronger reactivity was observed 
against the EU-antigen compared to the US-antigen. The EU-antigen diluted 1:150 
resulted in a significantly stronger IFN-γ-reactivity compared to a 1:750 dilution 
(ANOVA, P<0.05).  
Eighty-one sows from eight US-vaccinated stocks were examined in IFN-γ-RA (Fig. 
9c). The validation criteria led to the exclusion of 19.8% of samples from evaluation 
because of ten samples with ODSC <0.4 and six samples with ODPBS ≥0.2. The US-
antigen induced IFN-γ-reactivity and differences between US 1:150 and 1:750 were 
significant (Kruskal-Wallis test, P<0.05). EU-antigens remained at a low level except 
for single reactors.     
The highest level of IFN-γ-reactivity was observed for EU-antigen in 122 sows from 
13 EU-vaccinated stocks (Fig. 9d). Eight percent didn’t fulfil the validation criteria 
(three samples with ODSC <0.4 and seven samples with ODPBS ≥0.2). Differences 
between EU 1:150 and EU 1:750 were significant (Kruskal-Wallis test, P<0.05). US-
antigens remained almost negative with single samples showing low IFN-γ. 
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Figure 9: IFN-γ-reactivity of sows against vaccine derived antigens.  
Source: Own presentation 
Sows from non-vaccinated/non-infected (a, nstock=3, nsow=26), non-vaccinated/infected (b, nstock=3, 
nsow=24), US-vaccinated (c, nstock=8, nsow=65) and EU-vaccinated (d, nstock=13, nsow=112) herds. IFN-γ-
reactivity was expressed as a percentage of SC and the maximum reactivity was restricted to 100%. 
%ODPBS and %ODMARC145 were multiplied by -1. 
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4.6. Determination of appropriate cut-offs  
 
In order to define positive and negative results, non-vaccinated/non-infected stocks 
were used to set a cut-off value for the evaluation of infected and/or vaccinated 
stocks. Arithmetic means and standard deviations (s) of US and EU 1:150 were 
consulted for calculation of possible cut-off values. Table 4 gives an overview of 
calculations for single, two- and three-fold standard deviations. Considering the non-
vaccinated/non-infected animals to be negative, a cut-off value of 10% of SC seems 
to be an appropriate criterion for the differentiation of positive and negative samples. 
Table 5 (see page 35) gives an overview of the IFN-γ-positivity in the tested stocks 
on the basis of the cut-off value. 
 
 
Table 4: Determination of cut-off values with single, two- and three-fold standard deviations (% to SC).   
 
 arithmetic mean+1s arithmetic mean+2s arithmetic mean+3s 
US1:150 3.5342 6.3492 9.1642 
EU1:150 2.6501 4.5848 6.5195 
 
Source: Own presentation 
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4.7. IFN-γ-reactivity to field isolates  
 
So far, reactivity against EU- and US-antigens from vaccine virus was tested. In this 
study four antigens from wild-type isolates were included. Nineteen non-
vaccinated/non-infected sows from two stocks, 29 sows from three US-vaccinated 
stocks and 47 sows from five EU-vaccinated stocks were examined in IFN-γ-RA (Fig. 
10). Three US-vaccinated sows from one stock and four EU-vaccinated sows failed 
ODSC <0.4 and one EU-vaccinated sow failed ODPBS ≥0.2 so that 8.4% of samples 
were excluded from evaluation. An increased unspecific reactivity against non-
infected PAM was noticed. PAM reactivity was subtracted from reactivity to antigens 
from wild-type isolates. These antigens induced an IFN-γ-response in vaccinated 
sows comparable to that of vaccine-derived antigens although virus titers of wild-type 
isolates were about a thousand times lower. IFN-γ-reactivity to field isolates remained 
weak in non-vaccinated/non-infected herds. No significant differences existed 
between the four field isolates except of FI I being different from FI II and FI III 
(ANOVA, P<0.05) in EU-vaccinated stocks. Differences between EU-antigen and 
field isolates were not significant in US- and EU-vaccinated stocks as well.  
 
Figure 10: IFN-γ-reactivity of sows against field virus derived antigens. 
Source: Own presentation 
This Figure shows results of sows from non-vaccinated/non-infected (nstock=2, nsow=19), US-vaccinated 
(nstock=3, nsow=26) and EU-vaccinated (nstock=5, nsow=42) herds. The IFN-γ reactivity was expressed as 
a percentage of SC and the maximum reactivity was restricted to 100%. %ODPBS, %ODMARC145 and 
%ODPAM were multiplied by -1. 
Results  33 
 
4.8. Comparison of IFN-γ-test with other diagnostic tests 
 
Antibody ELISA and SNT were performed in parallel to IFN-γ-RA. A total of 244 sows 
from nine US- and 14 EU-vaccinated stocks, three non-vaccinated/infected stocks 
and three non-vaccinated/non-infected stocks were included. Annex 5 gives an 
overview of the comparison of ELISA, SNT and IFN-γ-RA results. 
 
4.8.1. Comparison with antibody ELISA 
 
No correlation was found between ELISA antibodies and IFN-γ-reactivity to US 1:150 
(Spearman correlation coefficient rho -0.0237; Fig. 11a). A slight positive correlation 
between ELISA antibodies and IFN-γ-reactivity to EU 1:150 was observed 
(Spearman correlation coefficient rho 0.537; Fig. 11b). 
 
4.8.2. Comparison with serum neutralisation test 
 
Animals were classified as SNT-positive or -negative for each viral genotype 
(PRRSV-US and -EU, respectively). Subsequently, animals were allocated to four 
groups SNT(US-/EU-), SNT(US+/EU+), SNT(US+/EU-) and SNT(US-/EU+) (Fig. 12). 
In group SNT(US-/EU-) only single samples developed an IFN-γ-response, whereas 
a striking reactivity to both US- and EU-antigens was observed in group 
SNT(US+/EU+). IFN-γ-reactivity to US-antigen in group SNT(US+/EU-) and to EU-
antigen in group SNT(US-/EU+) indicated a relationship between IFN-γ-response and 
SNT. IFN-γ-response to US-and EU-antigen was significantly different in groups 
SNT(US+/EU-), SNT(US-/EU+) and SNT(US+/EU+) (Kruskal-Wallis test, P<0.05). 
Irrespective of EU-specific neutralising antibodies, SNT-US-negative and -positive 
groups were different to each other regarding IFN-γ-reactivity to US-antigen. Vice 
versa, SNT-EU-negative and -positive groups were different in the IFN-γ-response to 
the EU-antigen. 
According to the IFN-γ-positivity of sows tested in IFN-γ-profiles (table 5), table 6 
gives an overview of the rate of SNT >2 of sows tested in the present examination. 
 
 
 
Results  34 
 
 
 
 
Figure 11: Comparison of antibody ELISA and IFN-γ-response.  
Source: Own presentation 
IFN-γ-response towards US 1:150 (a) and EU 1:150 (b) in nsow=248 (nstock (non-vaccinated/non-infected)=3, nstock 
(non-vaccinated/infected)=3, nstock (US-vaccinated)=9, nstock (EU-vaccinated)=14). IFN-γ-reactivity was expressed as a 
percentage of SC and the minimum and maximum reactivity was restricted to 0%, 100% (IFN-γ-RA) 
and 250% (antibody ELISA). Cut-off values of 10% (IFN-γ-RA) and 40% (antibody ELISA) are 
indicated by horizontal and vertical lines, respectively. 
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Figure 12: Comparison of SNT and IFN-γ-response. 
Source: Own presentation 
IFN-γ-response towards US 1:150 and EU 1:150 in nsow=248 (nstock (non-vaccinated/non-infected)=3, nstock (non-
vaccinated/infected)=3, nstock (US-vaccinated)=9, nstock (EU-vaccinated)=14). Animals were classified as SNT-positive or -
negative for each PRRSV-EU and -US (nsow(SNT(US-/EU-))=71, nsow(SNT(US+/EU+))=50, nsow(SNT(US+/EU-))=23, 
nsow(SNT(US-/EU+))=104). Subsequently animals were allocated to four groups. IFN-γ-reactivity for each 
group was determined. IFN-γ-reactivity was expressed as a percentage of SC and minimum and 
maximum reactivity in IFN-γ-RA was restricted to 0% and 100%. The cut-off value of 10% in IFN-γ-RA 
is indicated with a horizontal line. 
 
Table 5: IFN-γ-positivity in the different herds on the basis of a 10% cut-off value 
 IFN-γ-reactivity to US 1:150 IFN-γ-reactivity to EU 1:150 
US-vaccinated  28% 17% 
EU-vaccinated 5% 43% 
Non-vaccinated/infected  8% 29% 
 
Source: Own presentation 
 
Table 6: Rate of positive SNT (>2) in the different herds 
 US-SNT EU-SNT 
US-vaccinated  60% 43% 
EU-vaccinated 19% 90% 
Non-vaccinated/infected  8% 50% 
 
Source: Own presentation 
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4.9. Comparison of IFN-γ-reactivity considering different age groups 
 
The litter number per sow was used as an indirect correlate of age. IFN-γ-reactivity to 
US 1:150 and EU 1:150 was examined (Fig. 13a-d). Seventy-nine US-vaccinated 
(Fig. 13a), 120 EU-vaccinated (Fig. 13b), 24 non-vaccinated/infected (Fig. 13c) and 
26 non-vaccinated/non-infected sows (Fig. 13d) were assigned to three groups of 
litter no. “1./2.” including gilts (litter no. “0.”), “3./4.” and “5./6.”. The last group also 
included sows with litter no. “>6.”.  
In US-vaccinated stocks 14, 27 and 34 sows were assigned to the three groups. IFN-
γ-reactivity against both antigens (US + EU) increased with the litter number, but 
differences against EU-antigen were significant between groups “1./2.” and “5./6.” 
(ANOVA, P<0.05).  
Forty-five, 23 and 51 sows were included in groups in EU-vaccinated stocks. IFN-γ-
reactivity didn’t vary with the litter number.  
Non-vaccinated/infected herds with 6, 12 and 6 sows per group showed the highest 
IFN-γ-response to EU-antigen in the age group with one or two litters. Differences 
were again not significant (ANOVA, P>0.05). 
Non-vaccinated/non-infected herds remained unobtrusive.   
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Figure 13: Effect of litter number per sow on IFN-γ-reactivity. 
Source: Own presentation 
IFN-γ-reactivity to US and EU 1:150 in US-vaccinated (a, nstock=10, nsow=79), EU-vaccinated (b, 
nstock=15, nsow=120), non-vaccinated/infected (c, nstock=3, nsow=24) and non-vaccinated/non-infected 
sows (d, nstock=3, nsow=26) is shown. IFN-γ-reactivity was expressed as a percentage of SC. Minimum 
and maximum reactivity in IFN-γ-RA was restricted to 0% and 100%. The cut-off value of 10% in IFN-
γ-RA is indicated with a horizontal line. 
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4.10. Comparison of IFN-γ-reactivity with PBMC-counts in whole blood samples 
 
For comparison of IFN-γ-reactivity with PBMC-counts in whole blood samples, the 
amount of IFN-γ produced in stimulation control was used. PBMC in Li-Heparin 
stabilized whole blood samples of 257 sows were counted. No correlation was found 
between IFN-γ-reactivity and the number of PBMC (Spearman correlation coefficient 
rho 0.0134; Fig. 14). It had to be noticed that in many samples the PBMC numbers 
lay below the physiological limits. 
 
 
 
 
 
Figure 14: Effect of PBMC numbers on IFN-γ-reactivity of Li-Heparin stabilized blood samples to 
stimulation control (nstock=31, nsow=257).  
Source: Own presentation 
Reactivity towards SC is presented in pg/ml IFN-γ compared to the number of PBMC/µl whole blood. 
Physiological limits of number of PBMC (10.000-22.000/µlblood) are indicated with vertical lines. 
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4.11. Stability studies of antigens 
 
For evaluation of stability, MARC145, US- and EU-antigen were stored at 2 - 8°C and 
-20°C for 2, 4 and 8 weeks and tested in parallel. Storage at -80°C served as 
reference. Seventeen EU-vaccinated sows from two stocks were included in this 
experiment. Stability of antigens was examined in general (Fig. 15a) and for EU-
antigen separately per animal (Fig. 15b). Storage conditions had no significant effect 
on IFN-γ-reactivity regarding the EU-antigen (Kruskal-Wallis, P>0.05). Figure 15b 
shows that EU-antigens induced comparable IFN-γ-reactivity in the animals 
independent from storage conditions.  
 
4.12. IFN-γ-ELISpot 
 
IFN-γ-RA was compared with IFN-γ-ELISpot. The number of PBMC detected in the 
ELISpot is presented in Figure 18. Positive reacting cells could not be quantified until 
SC 0.1 µg/ml. PBMC from 24 sows originating from three EU-vaccinated stocks 
reacted positive to stimulation with EU-antigens. Stimulation with US-antigens led to 
IFN-γ-production in some cells as well. Reactivity to EU 1:150 is significantly different 
to EU 1:750 and to the US-antigens (ANOVA, P<0.05). Figure 19 compares data of 
IFN-γ-RA and IFN-γ-ELISpot by correlation. A slight positive correlation between both 
tests was observed (Spearman correlation coefficient rho 0.59).    
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Figure 15: Effect of storage conditions for antigens on IFN-γ-reactivity.  
Source: Own presentation 
Reactions in EU-vaccinated stocks (nstock=2, nsow=17) to antigens 1:150 in general (a) and per animal 
to EU-antigen (EU 1:150) (b) are shown. The validation criteria SC≥0.4 and ODPBS<0.2 were not 
applied. IFN-γ-reactivity was expressed as a a percentage of SC and maximum reactivity was 
restricted to 100%. %ODPBS and %ODMARC145 were multiplied by -1. 
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Figure 16: Quantification of IFN-γ-producing cells in an ELISpot (nstock=3, nsow=24). Source: Own 
presentation  
PBMCPBS was subtracted from PBMCMARC145. PBMCMARC145 was subtracted from PBMCUS and 
PBMCEU. PBMCPBS and PBMCMARC145 were multiplied by -1. 
 
 
 
 
Figure 17: Comparison of IFN-γ-RA and IFN-γ-ELISpot (nstock=3, nsow=24).  
Source: Own presentation 
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5. Discussion 
 
5.1. Preliminary considerations 
 
PRRS is a major problem in swine industry. Reproductive failure in sows and 
respiratory tract disease in growing pigs results in tremendous economic losses 
(Holtkamp et al., 2013; Neumann et al., 2005). It is further complicated by secondary 
bacterial infection in growing and fattening pigs (Drew, 2000; Zimmerman et al., 
2012) that require antibiotic treatment. Consequently, concerns about the 
development of antibiotic resistance of bacteria rose. Efforts to reduce the amount of 
antibiotics in veterinary medicine are confirmed by the 16th law amending the German 
medicine act (AMG) relating to the manufacture of medicines in Germany that will 
come into force on 1th April 2014 (Anonymous, 2013a). Vaccination against PRRSV 
might contribute to the reduction of antibiotic treatments. Several commercial 
attenuated and inactivated vaccines are currently in use. However, PRRSV-related 
problems are limiting the efficacy of vaccination: 
(1) PRRS-infection results in immunity to the homologous challenge that lasts for 
at least 600 days (Lager et al., 1997a). Ideally a vaccine should achieve 
similar protection. This kind of protection might cover antigenically related 
virus, but it decreases against more distantly related (heterologous) challenge 
virus (Labarque et al., 2004). Field virus strains are an unknown variable and 
new virus variants are continuously emerging (Labarque et al., 2004). This 
situation explains why vaccination with attenuated virus only reduces the level 
of viremia and severity of clinical disease.  
(2) Vaccination of piglets in the second or third week of life is recommended. The 
same vaccine for both sows and piglets is used. But if vaccination of sows 
induces sufficient neutralisation titers, these antibodies are transferred to 
piglets and neutralise the vaccine virus. Indeed passively transferred 
neutralising antibodies blocked infectivity of the homologous virus (Osorio et 
al., 2002). Assessment of vaccine-virus-specific neutralising antibody titers in 
piglets before vaccination might be helpful in order to pre-estimate the time of 
vaccination. 
(3) If vaccination of sows fails to induce homologous neutralising antibodies, 
newborn piglets are not protected by maternally derived antibodies. In EU-
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vaccinated herds with ongoing PRRSV-EU-circulation in weaned piglets a 
significant lower level of EU-neutralising antibodies are detected than in EU-
vaccinated herds without detection of PRRSV-EU in weaned piglets (Böttcher 
et al., accepted). Additionally, in those EU-vaccinated herds with ongoing virus 
circulation, sows of first and second parity showed a significantly lower level of 
neutralising antibodies as compared to older sows. This finding indicates a 
possible gap in herd immunity (Böttcher et al., accepted).  
Insufficient immune responses and gaps in immunity are not yet encountered 
systematically as a possible cause of vaccine failure. 
Efficacy of vaccination should be controlled by measuring the immune response after 
vaccination. Routine diagnosis of PRRS is based on PCR and antibody-ELISA. Both 
tests are of limited value in assessing the immune response after vaccination. 
Specifically, the ELISA detects non-neutralising antibodies that are directed against 
the nucleoprotein. Detection of wild-type PRRSV by PCR in vaccinated animals 
indicates an insufficient immune response, but the damaging event already occurred.  
 
In contrast to that, neutralising antibodies and pathogen-specific IFN-γ-responses 
would be appropriate correlates of protective immunity after vaccination against 
PRRSV. As SNT-titers are only reflecting the humoral immune response, vaccine-
virus-specific IFN-γ-reactivity mirrors cellular immunity. Analysis of both allows a 
more meaningful diagnosis of PRRSV-immunity. 
 
5.2. Complexity of IFN-γ-recall-assay (RA)-validation 
 
The OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2013 
(Anonymous, 2013b; online English version) provides guidelines for development 
and validation of diagnostic tests. These guidelines are helpful for the validation of 
serological tests, but some problems rose regarding the validation of IFN-γ-RA:  
(1) In case of serological tests a panel of sera with known status, probably stored 
at -80°C, might be used. However, due to the reliance of IFN-γ-RA on 
stimulation of viable PBMC, blood samples have to be collected freshly for 
each testing. As a routine diagnostic laboratory without an experimental 
animal facility, animals with a defined status were not available. Only samples 
from the field were accessible. Validation relied on blood samples from routine 
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diagnostic submissions. Animals were defined by the infection status of herds 
regarding vaccination, presence or absence of antibodies in ELISA and SNT 
as well as detection of PRRSV by PCR. 
(2) Common diagnostic tests only define results as positive or negative. However, 
tests for immunity should provide quantitative outputs. The amount of IFN-γ is 
frequently expressed e.g. as pg/ml or in case of ELISpot as spots per tested 
cells. This kind of quantification does not reflect the animal’s general ability to 
produce IFN-γ and the quality of the PBMC in blood samples to produce IFN-
γ. A negative value after stimulation with PRRSV-antigen might reflect a 
general inability of PBMC to produce IFN-γ. A SC had to be included as a 
reference and an appropriate concentration had to be determined in order to 
express the pathogen-specific IFN-γ-reactivity as a percentage of the SC. 
(3) Cut-off values are imperative for each diagnostic tool. At this early stage of 
validation no gold-standard is available for analysis strategies. Additionally, a 
cut-off for IFN-γ-positivity that differentiates infected from negative animals 
does not necessarily correspond to the level of protection. Therefore only a 
scale of IFN-γ-reactivity was provided on which the latter might be selected. 
(4) Aside from SC additional appropriate controls had to be chosen. It has to be 
kept in mind that animals are repeatedly vaccinated with vaccines produced in 
cell-culture. Contaminants in vaccines might induce unspecific IFN-γ-reactivity 
and has to be ruled out with a cell control. 
(5) As mentioned previously, IFN-γ-testing requires viable cells. The time span 
between sampling and testing is critical. The stimulation of cells was 
performed within eight hours after blood collection. Blood samples were 
transported directly from the farm to the lab. Testing of blood samples not later 
than 24 hours after collection is crucial for the implementation of an IFN-γ-RA 
in a routine diagnostic laboratory. 
(6) The immune status of an animal changes in the course of infection or 
vaccination. Different levels of IFN-γ-producing cells are expected e.g. after 
primary infection/vaccination, after secondary (booster) infection/vaccination or 
after clearance of the virus as it is the case late after infection/vaccination, 
when only few memory cells are present in the circulation. This issue needs to 
be addressed in defined animal trials which are not addressed in the current 
study. 
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Despite this extensive list of problems a promising prototype of a PRRSV-IFN-γ-RA 
was provided and its general feasibility was demonstrated. A comprehensive 
validation considering the guidelines of the OIE Manual of Diagnostic Tests and 
Vaccines for Terrestrial Animals 2013 (Anonymous, 2013b; online English version) 
was not possible due to limitations of time, material and costs. Further examinations 
are necessary for improvement of the provided test system.  
 
5.3. Comparison of IFN-γ-RA and ELISpot 
 
The IFN-γ-RA and the IFN-γ-ELISpot were compared. The following aspects were 
considered: 
(1) The IFN-γ-ELISpot is five to ten-fold more expensive than the IFN-γ-RA. 
(2) The IFN-γ-RA detects IFN-γ in plasma. Therefore it is sufficient to stimulated 
whole blood samples. In contrast to that, PBMC need to be purified, counted 
and set to a defined number of PBMC in case of ELISpot. In IFN-γ-RA the 
number of antigens (or e.g. the dilutions of antigens) might be easily extended 
without a dramatic increase of laboratory work. An increase of the number of 
antigens in ELISpot might require an additional PBMC-purification. 
(3) The IFN-γ-ELISpot requires a longer incubation period during stimulation (20-
24 hours) compared to IFN-γ-RA (16 hours). 
(4) Photometers to read ODs of IFN-γ-RA are available in every routine diagnostic 
laboratory. An ELISpot-reader is required to count stained spots. Additionally, 
each plate needs to be adjusted and assessment of data takes more time.  
(5) The detectability of the ELISpot is higher since single IFN-γ-producing cells 
are detected. This is exemplified by the SC: A concentration of 0.6 µg/ml was 
required for IFN-γ-RA whereas a lower concentration of 0.1 µg/ml allowed 
counting of single spots.  
In summary, several advantages are in favour of IFN-γ-RA for routine use 
compared to IFN-γ-ELISpot. Nevertheless, the IFN-γ-ELISpot as a second test 
was established. The same blood samples were tested with IFN-γ-RA and 
ELISpot. Blood samples were prepared for IFN-γ-ELISpot as published (Dotti et 
al., 2013; Molina et al., 2008; Piras et al., 2005; Zuckermann et al., 2007). Similar 
to the results of Dotti et al. (2013) a good agreement between the IFN-γ-reactivity 
both in IFN-γ-RA and ELISpot was found. Results of Dotti et al. (2013) indicated a 
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lack of PRRSV-specific IFN-γ-response in infected pigs, whereas in the present 
examinations a clear IFN-γ-response to EU-antigen in EU-vaccinated herds was 
observed for several animals in IFN-γ-RA and ELISpot as well. Contrary, Díaz & 
Mateu (2005) rose concerns about the interpretation of IFN-γ-ELISpot in 
comparison to the IFN-γ-RA. They considered that no correlation exists between 
the number of IFN-γ-secreting cells in the ELISpot and IFN-γ-intensity in the recall 
assay. Furthermore, densities of seeded cells in the ELISpot need to be adapted 
with the age of tested animals because IFN-γ-frequencies of cytokine secreting 
cells may vary with the age (Díaz & Mateu, 2005).  
The IFN-γ-RA was selected because of several advantages towards the ELISpot, 
which are less expenditure of time in sample preparation, inclusion of several 
antigens due to more sample material, better evaluability of raw data and lower 
costs of test material. Nevertheless, the IFN-γ-ELISpot probably should be taken 
into consideration as a further test for definition of cut-offs for protective IFN-γ-
reactivity. 
 
5.4. Selection of the test kit for the detection of IFN-γ 
 
Two commercial test kits for the detection of IFN-γ in plasma of stimulated blood 
samples were included in this study. Both test kits provided standards. The standard 
of test kit A had to be diluted in 1/2-steps and covered the range from 4000 down to 
62.5 pg/ml, whereas in kit B three concentrations 1000, 100 and 10 pg/ml had to be 
included. Kit A was unable to discriminate an IFN-γ-concentration of 10 pg/ml from 
the negative standard. Two disadvantages were observed for test kit B. Firstly, it 
showed a significantly higher interday variation compared to the interplate variation 
(Fig. 2, Chapter 4.1.). Secondly, unstimulated plasma samples (PBS) showed an 
increased reactivity than in kit A (Fig. 4, Chapter 4.2.). With regard to Figure 4 and 
the following figures, it should be kept in mind that undesirable reactivity as observed 
in PBS-control or against MARC145 are expressed as negative values (multiplied by 
-1), indicating that PBS- and MARC145-reactivity was subtracted from SC and 
specific antigens, respectively. An unspecific IFN-γ-reactivity in PBS-control was also 
noticed by Dotti et al. (2013). They explained this by a concurrent infection of animals 
with other pathogens. However, as IFN-γ-productivity in the PBS control in present 
examinations only was noticed in one of the two test kits it was assumed to be a test 
Discussion  47 
 
specific problem. Indeed, kit B relies on two mouse MAb, one as capture- and the 
second as detection antibody. Consequently, anti-mouse IgG-antibodies in pig sera 
might bridge unspecifically between both MAbs, which results in a false positive 
signal. In contrast to that, kit A uses a mouse MAb as capture and polyclonal anti-
IFN-γ-goat-IgG as detection antibody. Additionally, goat serum is added to the 
detection antibody. An important further question concerns the detectability of IFN-γ. 
A concentration of 62.5 pg/ml IFN-γ resulted in a net-reactivity of 40-50 mOD in test 
kit A (Fig. 2a and b). Dotti et al. (2013) presented their results of a PRRSV-IFN-γ-
ELISA in mOD. They determined cut-offs by testing whole blood samples of SPF 
pigs. They scored samples positive if the OD in PRRSV-stimulated whole blood 
cultures was at least 50 mOD higher than in the corresponding mock-stimulated and 
unstimulated cultures. Unfortunately detectability was not assessed in that study. 
Mikkelsen et al. (2012) analysed the IFN-γ-reactivity against Mycobacterium avium 
ssp. paratuberculosis (MAP) in cattle. They expressed data as pg/ml. MAP non-
infected herds were used to define cut-off values of ≥1000 pg/ml and <150 pg/ml for 
positive and negative control, respectively. IFN-γ-reactivity to specific antigens was 
corrected by subtraction of IFN-γ-response of PBS-control. Their results ranged from 
1 to 10.000 pg/ml.  
With detection of higher amounts of IFN-γ, Subharat et al. (2012) chose ng/ml for 
presentation of IFN-γ-quantity. They calculated IFN-γ-reactivity to MAP against a 
standard curve prepared with recombinant IFN-γ. The cut-off value for positive IFN-γ-
reactivity was calculated from the mean and two standard deviations of the value for 
control animals and was set to 3.80 ng/ml IFN-γ. They gained maximum IFN-γ-
reactivity of 40 ng/ml. 
In their study of IFN-γ-reactivity against Coxiella burnetii, Roest et al. (2013) used a 
positive control (stimulation control) in the ELISpot assay as a reference for IFN-γ-
responses in goats. IFN-γ-reactivity previously was corrected by subtraction of IFN-γ-
response to the medium control. 
According to Roest et al. (2013) SC was chosen as a reference for IFN-γ-reactivity to 
specific antigens in the present experiments. IFN-γ-standard in pg/ml was used for 
the calibration of the SC. 
Kit A was selected for further IFN-γ-examinations. Standard series was well 
distributed within the measuring range of the photometer. Kit A further showed lower 
interday variation in standards and lower unspecific reactivity to PBS. 
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5.5. Stimulation and PBS control 
 
The SC was included for two reasons:  
(1) confirmation of viability and ability of PBMC to produce IFN-γ and  
(2) as a positive control to express the pathogen-specific IFN-γ-response as percent. 
A concentration of 0.6 µg/ml of SC resulted in an IFN-γ-reactivity well distributed in 
the measuring range of the ELISA, whereas lower concentrations often induced weak 
IFN-γ-production (Fig. 4). To ensure correct interpretation of sample reactivity, a 
minimum ODSC of 0.4 was defined. Using this validation criterion 93.5% of the 
samples gave valid results (SC 0.6 µg/ml).  
PBS served as negative control and a maximum ODPBS was set to 0.2. Considering 
both validation criteria SC and PBS 87% of the samples in IFN-γ-profiles were valid. 
This value is important when the number of samples per herd or group is planned. 
 
5.6. Unspecific IFN-γ-reactivity to control antigen 
 
A remarkable reactivity against the control antigen (MARC145) was observed (Fig. 
5). FCS was identified as the source of this unspecific reactivity. FCS is frequently 
used as an additive in cell culture. Martelli et al. (2009) and Ferrari et al. (2013) 
examined 5 to 16 week old pigs (vaccinated and challenged by natural exposure) 
with an IFN-γ-ELISpot. They resuspended PBMC after purification in an FCS-
supplemented medium (10% FCS). As negative control they used cells in the 
respective medium. They did not use mock-infected cells as a further control antigen 
for stimulation. None of them reported unspecific reactivity in the negative control. 
The reason for this might be the age of the animals. In contrast to that in the present 
studies only sows were tested, which had been repeatedly vaccinated.  
Molina et al. (2008) prepared the viral antigen in a medium supplemented with 5% 
FCS. The PRRSV-antigen was semipurified by a sucrose gradient centrifugation and 
a medium without supplementation with FCS served as negative control in the IFN-γ-
ELISpot.  Two week old PRRSV negative piglets were inoculated with PRRSV and 
bled at 1- to 2-week intervals until the age of 30 weeks. They gained PRRSV-specific 
IFN-γ-responses, but neither an unspecific reactivity to the control antigen nor the 
reason for purification of the virus was reported.   
Notably two authors reported about unspecific reactivity against the control antigen:  
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(1) Dotti et al. (2013) used 2% FCS for virus propagation and preparation of the 
control antigen. The antigens were obtained by freezing and thawing cell 
cultures, which is similar to the procedure in the current study. The authors 
observed an IFN-γ-response to the control antigen and speculated about 
damage-associated molecular pattern molecules causing unspecific 
reactivity. However, after subtraction of the reactivity against the control 
antigen most samples scored negative.  
(2) Zuckermann et al. (2007) resuspended purified PBMC in medium with 5% 
FCS. Unstimulated PBMC in this medium served as negative control. No 
PBS control was carried along. One of their animal groups, treated with a 
killed vaccine in adjuvant, developed a high frequency of non-PRRSV-
specific IFN-γ-producing cells. The IFN-γ-reactivity of negative controls was 
also subtracted from specific IFN-γ-responses. They assumed the unspecific 
reactivity to be an effect mediated by a component of the vaccine.  
Vaccines, at least the US vaccine used in this study, also contain FCS. It should 
be kept in mind that other vaccines – vaccines against porcine circo virus 2, 
porcine parvo virus or swine influenza virus – also may contain FCS. So it might 
be possible that frequent vaccination leads to unspecific reactivity against the 
FCS. Therefore, alternative methods for preparation of virus stocks had to be 
chosen. Purification of virus preparation by means of sucrose gradients or the 
production of antigen without supplementation of FCS were considered. In this 
study, the focus was on cell lysates of vaccine virus collected in PBS in order to 
sustain sufficiently high virus titers. However, titers of field virus after infection of 
PAM were significantly lower than those of vaccine virus on MARC145-cells. In 
order to obtain field virus antigens with appropriate titers FCS was substituted by 
horse serum. 
 
5.7. Feasibility of IFN-γ-RA  
 
So far, the IFN-γ-RA assay was selected as suitable test method and one test kit out 
of two was chosen for further investigations. The SC was adjusted as reference for 
IFN-γ-reactivity against pathogen-specific antigens. Unspecific reactivity against 
control antigen was reduced by an optimisation of antigen preparation. Appropriate 
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antigens for stimulation of whole blood samples were provided. At this point IFN-γ-RA 
was ready for feasibility studies. 
The aim of a feasibility study is to assess if non-infected animals are identified as 
negative and infected as positive. This aim requires that non-infected and infected 
animals are defined as such by a gold-standard. The commercial ELISA might be 
regarded as such a gold standard. But ELISA-antibodies are developed early after 
infection and cellular immune response is delayed. This might result in 
misclassification of animals. To circumvent this problem we defined the status of sow 
herds. Therefore, blood samples of sows from non-vaccinated/non-infected, non-
vaccinated/infected, US- or EU-vaccinated stocks irrespective of infection were 
studied with IFN-γ-RA. Negative stocks were defined as ELISA-, SNT- and PCR-
negative. The absence of IFN-γ-reactivity is expected in these stocks. Additionally, 
this group was used to estimate the cut-off value for positivity in vaccinated and non-
vaccinated/infected stocks. Sows in negative herds tested negative in IFN-γ-RA. 
Single false-positive animals are no problem because the IFN-γ-RA will not be 
applied for certification of negative herds. Regarding infected and vaccinated herds a 
degree of genotype-specificity was observed. US- and EU-IFN-γ-reactivity was 
preferentially observed in US-vaccinated and EU-vaccinated herds, respectively. 
Dominance of EU-IFN-γ-reactivity in non-vaccinated/infected herds is in agreement 
with EU-wild-type infection. Remarkably, a similar pattern was observed for the SNT 
(Böttcher et al., 2006; Böttcher et al., accepted). 
It is the aim of the IFN-γ-RA to detect gaps in immunity. Such gaps might be age-
related. Therefore, the available sows were analysed by their litter number as a 
correlate of age. In US-vaccinated herds a stronger IFN-γ-reactivity was observed 
against US-antigen. However, sows with litter numbers >4 showed the strongest 
reactivity and it was directed against both antigens US and EU. This picture might 
indicate an infection with EU-virus when younger sows were not yet part of the herd. 
In contrast to that, no age-difference was observed in EU-vaccinated sows. A strong 
reactivity in non-vaccinated/infected herds in the group 1./2. litter number might be 
explained by an infection as piglet or gilt of these animals. In summary, IFN-γ-RA 
provided remarkable differences between animals and herd groups. 
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5.8. Comparison of IFN-γ-test with ELISA and SNT 
 
Lopez & Osorio (2004) drawed a picture about the development of viremia, ELISA-
antibodies, neutralising antibodies and IFN-γ-response over time. No correlation was 
observed between ELISA-antibody and IFN-γ-RA. This finding might be due to the 
fact that IFN-γ-RA differentiated between the EU- and US-genotype, whereas ELISA 
does not differentiate between genotypes. Additionally, the time difference between 
the development of ELISA-antibody and cellular immunity might be important. Both 
development of neutralising antibodies and IFN-γ-responses are retarded after 
infection, whereas ELISA-antibodies are detected early after infection.  
A similar genotype specificity was observed for neutralising antibodies and IFN-γ-RA 
(Fig. 12, Chapter 4.8.2.). However, IFN-γ-reactivity was not always detected in 
animals with neutralising antibodies. It should be kept in mind that IFN-γ-reactivity 
might decrease to undetectable level after successful development of immunity 
because immune cells are down regulated to a low number of memory cells.  
Data of Figure 12 might also indicate a biased immune response. Ideally, a well-
balanced immune response should comprise both cellular and humoral immunity. If in 
a portion of animals only neutralising antibodies but no IFN-γ-response are detected, 
this could indicate a rather unfavourable immune response. Consequently, IFN-γ-RA 
might be of remarkable interest in order to detect such an unbalanced immune 
response.  
It should be kept in mind that the feasibility study relied on non-randomly collected 
blood samples so that obtained data are not representative. 
 
5.9. IFN-γ-reactivity against field virus isolates  
 
The immune response against field virus isolates is so far an unknown variable which 
cannot be assessed easily. Lager et al. (1999) examined the humoral immune 
response in gilts after experimental infection with virulent field virus strains of 
PRRSV. They compared it to the immune response after vaccination with an 
attenuated-virus vaccine strain of PRRSV and found a varying development of 
humoral immunity towards the virus variants. Several PRRSV antigens were included 
in the present study to examine the differences in cellular immune response against 
PRRSV isolates. Field virus is currently detected by PCR and was characterized by 
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sequencing. However, such sequence data are of limited value regarding prediction 
of antigenicity and possible cross reactivity or cross protection. Since 2006, virus 
isolation on PAM in routine diagnosis was implemented so that a panel of PRRSV 
field isolates is available to address immune reactivity to these viruses. In this study 
four PRRSV field isolates were included for stimulation of blood samples parallely to 
stimulation with regular antigens. For evaluation of reactivity of blood samples 
homology of field virus strains to the reference strain Lelystad virus and virus titers of 
antigens had to be considered. Included field virus strains had a homology ranging 
from 87% to 93% to reference strain Lelystad. Field virus isolates had lower titers of 
infectivity (104 to 106/ml). Therefore, a lower dilution (1:15) in stimulation of blood 
samples was chosen. Antigens from vaccine virus showed titers of 107.5 and 107.8/ml 
and were used at a dilution of 1:150 in stimulation of blood samples. Nevertheless, a 
remarkable reactivity against field virus strains was observed in EU- and US-
vaccinated stocks. These results might indicate a higher power of field virus to induce 
IFN-γ-responses. So attenuation of virus which is the case for vaccine virus might 
coincide with reduced power to induce IFN-γ-responses. Field virus isolates are 
propagated on PAM, cells of the innate immune response, so the cellular background 
of the antigen might explain a stronger reactivity, too. Reactivity of US-vaccinated 
sows with field virus-antigens might indicate some cross-protection by US-vaccine. 
However, this needs to be addressed in further studies. Non-vaccinated/non-infected 
sows showed a significantly weaker IFN-γ-reactivity than vaccinated/infected sows. 
Single reactors in non-vaccinated/non-infected herds might pinpoint to such an 
unspecific reactivity against field virus isolates. However, it should be kept in mind 
that these herds were characterized by a single testing. So, a history of PRRSV-
infection of single animals cannot be ruled out. Mock-infected PAM induced a 
stronger IFN-γ-reactivity than mock-infected MARC145-controls, but both were 
subtracted from specific reactivity. Currently, vaccine virus is adapted to PAM in 
order to compare vaccine virus and field virus isolates by IFN-γ-reactivity. 
Díaz et al. (2012) were the first reporting cell-mediated responses against two 
different PRRSV field strains of the EU-genotype. They isolated the virus strains from 
infected farms and produced viral stocks in PAM. In two experiments they inoculated 
pigs with the two EU PRRSV strains and determined IFN-γ-producing cells with the 
ELISpot after in vitro and in vivo challenge with the homologous and heterologous 
virus strain as well. Interestingly, one of the two isolates induced higher frequencies 
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of IFN-γ-positive cells in both experiments. Ferrari et al. (2013) compared IFN-γ-
reactivity in pigs previously vaccinated and subsequently exposed to two field 
isolates. Heterologous challenge with one field virus isolate induced similar IFN-γ-
reactivity compared to homologous challenge with the vaccine virus strain, whereas 
the other field isolate induced lower IFN-γ-reactivity.  
In summary, the presented IFN-γ-RA offers a possibility to include a panel of 
antigens derived from field virus isolates. It is an important advantage of the IFN-γ-
RA compared to the neutralisation assay as field virus isolates are not easily included 
in neutralisation assays. 
 
5.10.  Stability studies 
 
So far stability of antigens for IFN-γ-RA or IFN-γ-ELISpots was not studied. 
Therefore, a stability study of antigens was included in order to optimise testing 
conditions.  
Antigens were tested for their stability using different storage conditions. Stimulation 
capability of specific antigens was not affected by storage conditions. This might be 
explained by linear epitopes inducing IFN-γ-responses whereas neutralising 
antibodies are frequently directed against conformational epitopes. 
 
5.11. Conclusion and future prospects 
 
General feasibility of the IFN-γ-RA has been demonstrated. A provisional cut-off 
value was defined to differentiate IFN-γ-positive and -negative animals. However, a 
conclusion about the relevance for protection cannot be drawn. It is still not possible 
to give a statement on the amount of IFN-γ being protective against PRRSV. IFN-γ-
reactivity to specific antigens was rather weak. This result might be explained by the 
immunobiology of PRRSV-infection. 
A strong IFN-γ-reactivity to field virus compared to vaccine virus derived antigens is 
of remarkable interest. Therefore, the presented IFN-γ-RA is a promising tool to 
further elucidate the immune response against the field virus. Regarding unspecific 
IFN-γ-reactivity against mock-infected PAM, further investigations with vaccine 
derived antigens adapted to PAM are indicated. 
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Blood samples principally were stimulated with specific antigens at the day of 
collection. For routine diagnosis this procedure could be a limiting factor. The ability 
of cells to respond with IFN-γ rapidly decreased. It is a major disadvantage for routine 
use. However, antigens turned out to be very stable. This is explained by linear 
epitopes recognised by PBMC.  
The present IFN-γ-RA was established with samples collected from sows. The IFN-γ-
RA showed a similar genotype specificity as the SNT. The application of IFN-γ-RA on 
samples from piglets or fatteners remains to be investigated.   
A cross-sectional study in sow herds with different vaccination or infection history is 
currently planned to demonstrate the added value of the IFN-γ-RA. In this study IFN-
γ-RA, SNT, ELISA and PCR will be implemented in order to draw a more complete 
picture of PRRSV-infection. 
In summary, the IFN-γ-RA can be used for measuring the cellular immunity. The SNT 
and the IFN-γ-RA provide two good possibilities to measure appropriate correlates of 
protective immunity after vaccination against PRRSV. 
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6. Summary (English) 
 
Porcine Reproductive and Respiratory Syndrome (PRRS) is a major problem in the 
swine industry that results in tremendous economic losses. Attenuated live-vaccines, 
either based on the EU- or the US-genotype, are available for the control of clinical 
disease. Currently the immune status after vaccination is only controlled by serum 
neutralisation test (SNT). This study was carried out to establish an IFN-γ-recall 
assay (IFN-γ-RA) examining the cellular immune response against PRRSV, too.  
In the course of routine diagnosis, blood samples were randomly collected from non-
vaccinated/non-infected, non-vaccinated/infected and US- or EU-vaccinated herds. A 
panel of pathogen-specific antigens derived from vaccine virus and field virus isolates 
was implemented. Appropriate controls (stimulation control (SC), PBS-control and 
mock-infected cell cultures) were included in order to express results as percent of 
SC-reactivity and to circumvent an observed unspecific reactivity against cell culture 
ingredients. 
A provisional cut-off (10%) was defined by analysis of non-infected herds. Based on 
this cut-off value, 28% of sows in US- and 43% of sows in EU-vaccinated herds 
reacted with US- and EU-antigens, respectively. 29% of sows from non-
vaccinated/infected herds preferentially reacted against EU-antigen. Thus the 
developed IFN-γ-RA showed a similar genotype specificity as observed for the SNT. 
Field virus derived antigens were included. Compared to vaccine derived antigens, a 
relatively stronger reactivity in IFN-γ-RA was observed against the field virus derived 
antigens. This might be due to attenuation of vaccine virus or by the cell culture used 
for production of antigens. As the field virus was propagated on porcine alveolar 
macrophages an effect of these cells on results cannot be ruled out. 
A remarkable stability of antigens was demonstrated. However, blood samples still 
need to be stimulated the day of sampling as the ability of cells to respond with IFN-γ 
rapidly decreased.  
Nevertheless, the presented IFN-γ-RA is a promising tool to further analyse the 
cellular immune response in PRRSV-vaccinated sows. 
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7. Summary (German) 
 
Das Porcine Reproductive and Respiratory Syndrome (PRRS) ist ein großes Problem 
in der Schweinehaltung, das zu enormen wirtschaftlichen Verlusten führt. Attenuierte 
Lebendimpfstoffe, die sowohl auf dem EU- als auch auf dem US-Genotyp basieren, 
stehen für die Kontrolle klinischer Erkrankungen zur Verfügung. Derzeit wird der 
Immunstatus nach einer Impfung lediglich mit dem Serumneutralisationstest (SNT) 
überprüft. In der vorliegenden Studie wurde ein IFN-γ-Test entwickelt, der auch die 
zelluläre Immunantwort gegen das PRRSV bestimmt.  
Im Rahmen von Routineuntersuchungen wurden Blutproben von Sauen aus nicht-
geimpften/nicht-infizierten, nicht-geimpften/infizierten und US- oder EU-geimpften 
Beständen zufällig entnommen. Eine Auswahl an Pathogen-spezifischen Antigenen 
von Impfvirus- und Feldvirusisolaten wurden in die Untersuchung einbezogen. 
Geeignete Kontrollen (Stimulationskontrolle (SC), PBS-Kontrolle und nicht-infizierte 
Zellkulturen) wurden mitgeführt, um die Ergebnisse prozentual zu den IFN-γ-
Reaktionen der SC darzustellen und um unspezifische Reaktionen gegen 
Zellkulturbestandteile zu erfassen. 
Ein vorläufiger Cut-off (10%) wurde mit Hilfe nicht-geimpfter/nicht-infizierter Herden 
festgelegt. Basierend auf diesem Cut-off reagierten in US- und EU-geimpften 
Beständen 28% der Sauen mit den US- und 43% der Sauen mit den EU-Antigenen. 
Damit wies der entwickelte IFN-γ-Test eine zum SNT vergleichbare Genotyp-
Spezifität auf. Im Vergleich zu den Impfvirus-Antigenen wurden gegen die Feldvirus-
Antigene relativ stärkere Reaktionen beobachtet. Die Attenuierung der 
Impfvirusstämme oder die für die Produktion der Antigene verwendeten Zellkulturen 
sind mögliche Erklärungen. Da die Feldisolate auf porzinen Alveolarmakrophagen 
vermehrt wurden, kann ein Einfluss dieser Zellen auf die Ergebnisse nicht 
ausgeschlossen werden. 
Die Haltbarkeit der Antigene war sehr gut. Blutproben müssen jedoch weiterhin am 
Tag der Entnahme stimuliert werden, da die Fähigkeit der Zellen zur IFN-γ-
Produktion mit zunehmendem Abstand von der Entnahme abnimmt. 
Dennoch stellt der IFN-γ-Test ein vielversprechendes Werkzeug für weitere 
Untersuchungen der zellulären Immunantwort in PRRSV-geimpften Beständen dar.   
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Annex 
 
Annex 1. Material 
 
Annex 1.1: Cell cultures and antigens 
Material Source Information 
MARC145 cells Provided from the 
Collection of Cell lines in 
Veterinary Medicine 
(CCLV), Friedrich-Loeffler-
Institute (FLI), Riems 
Clones of the cell line MA-
104 extracted from the 
fetal kidney of the African 
Green Monkey 
Porcine alveolar 
macrophages 
Extracted in own 
laboratory 
 
Ingelvac® PRRS MLV Boehringer, Ingelheim, 
Germany 
Genotype 2  
vaccine virus 
Porcilis® PRRS MSD/Intervet, Boxmeer, 
Netherland 
Genotype 1 
vaccine virus 
Field isolates  Cultivated in own 
laboratory 
V2276/I, V1192, V683, 
V995 
Control antigens Prepared in own 
laboratory 
Supernatant of uninfected 
cell culture 
Pokeweed mitogen Sigma-Aldrich®,  
St. Louis, USA 
Stimulation control 
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Annex 1.2: Media and reagents 
Material  Source Information 
MEM Earle’s 
(Earle’s Minimal Essential 
Medium) 
BIOCHROM AG, Berlin, 
Germany 
 
Basic medium for 
MARC145, supplemented 
with 10mM HEPES-Buffer, 
1% NEA and 1% 
Pen/Strep 
RPMI 1640 
(Roswell Park Memorial 
Institute Medium) 
BIOCHROM AG, Berlin, 
Germany 
 
Basic medium for PAM, 
supplemented with 1% 
NEA, 1% Pen/Strep and 
1% L-glutamine 
PBS Dulbecco 
w/o Ca2+, w/o Mg2+ 
BIOCHROM AG, Berlin, 
Germany 
 
PBS Dulbecco (10x) BIOCHROM AG, Berlin, 
Germany 
 
Ultra Pure Water BIOCHROM AG, Berlin, 
Germany 
 
Fetal Bovine Serum/ Fetal 
Calf Serum  
gamma-irradiated 
Life Technologies™, 
GIBCO®, Carlsbad, 
California 
 
Donor Horse Serum BIOCHROM AG, Berlin, 
Germany 
 
HEPES-Buffer 
(1M) 
BIOCHROM AG, Berlin, 
Germany 
 
Non-essential amino acids 
(100x) 
BIOCHROM AG, Berlin, 
Germany 
 
Penicillin/streptomycin 
10.000 U/ml/  
10.000 µg/ml 
BIOCHROM AG, Berlin, 
Germany  
 
Gentamycin 
10 µg/ml 
BIOCHROM AG, Berlin, 
Germany  
 
Patricin 
50 µg/ml 
BIOCHROM AG, Berlin, 
Germany  
 
Baytril® 5% Bayer, Leverkusen, 
Germany 
 
L-glutamine 
200mM 
BIOCHROM AG, Berlin, 
Germany  
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Annex 1.2: Media and reagents (continuation) 
Material  Source Information 
Dimethyl sulfoxide Sigma-Aldrich®, St. Louis, 
USA 
 
Tween® 20 Merck Millipore, 
Darmstadt, Germany 
 
Bovine serum albumin Sigma-Aldrich®, St. Louis, 
USA 
 
Normal Goat Serum R&D Systems®, 
Minneapolis, USA 
 
CHECKIT* TMB substrate Idexx Laboratories, 
Westbrook, USA 
Substrate solution 
CHECKIT* stop solution 
TMB  
Idexx Laboratories, 
Westbrook, USA 
Stop solution 
Ficoll-Paque™ PLUS GE Healthcare, 
Buckinghamshire,  
Great Britain 
 
Complement sera from 
guinea pig 
776 units/ml 
Sigma-Aldrich®, St. Louis, 
USA 
 
Trypan blue Serva Feinbiochemica 
GmbH, Heidelberg, 
Germany 
 
FITC conjugated 
monoclonal anti-PRRSV 
antibody 
BioX Diagnostics, Jemelle, 
Belgium 
 
FITC anti-mouse IgG Sigma-Aldrich®, St. Louis, 
USA 
 
Glycerol Sigma-Aldrich®, St. Louis, 
USA 
 
DABCO Sigma-Aldrich®, St. Louis, 
USA 
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Annex 1.3: Test kits 
Material Source Information 
DuoSet® ELISA porcine 
IFN-γ kit 
R&D Systems®, 
Minneapolis, USA 
IFN-γ-RA 
kit A 
Porcine IFN-γ-RA kit 
development 
Mabtech, Stockholm, 
Sweden 
IFN-γ-RA 
kit B 
Porcine IFN-γ ELISpot kit R&D Systems®, 
Minneapolis, USA 
IFN-γ-ELISpot 
Herd Check* PRRS X3, 
Porcine Reproductive and 
Respiratory Syndrome 
Virus Antibody Test kit 
Idexx Laboratories, 
Westbrook, USA 
Antibody ELISA 
QIAamp® Viral RNA Mini-
kit 
QIAGEN®, Hilden, 
Germany 
Kit includes buffers and 
2ml MiniSpin Column 
collection tube 
VIROTYPE® PRRSV Labor Diagnostik GmbH, 
Leipzig, Germany 
Real time Multiplex RT-
PCR Test kit for Detection 
of EU, NA and HP PRRS 
viruses 
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Annex 1.4: Laboratory equipment and supplies 
Material Source Information 
Cell culture vessels Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
Nunc™ Easy Flasks™, 
Nunclon™ Delta-treated, 
175 v/c, 75 v/c and 25 v/c 
96-well microtitration plate Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
Nunc MicroWell 96-Well 
Microplates, 
Nunclon™ Delta Surface, 
Flat Bottom 
48-well multidishes Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
Nunclon™ ∆surface 
Cell tubes Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
For PAM/MARC145, 
Nunclon™ ∆surface,     flat 
bottom 
High protein binding ELISA 
plate 
Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
Nunc-Immuno™ Plates, 
MaxiSorp 
Micro tubes 1,5ml Sarstedt, Nürnbrecht, 
Germany 
PP, with attached PP cap 
Optical Tube Strips Agilent Technologies, 
Santa Clara, California 
8x Strip 
Stratagene M3005P Agilent Technologies, 
Santa Clara, California 
 
Mx Pro QPCR software Agilent Technologies, 
Santa Clara, California 
 
Cell-Dyn 3500 Abbott, Illinois, USA  
Fuchs Rosenthal counting 
chamber 
Blaubrand®, 
Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
 
Neubauer counting chamber Blaubrand®, 
Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
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Annex 1.4: Laboratory equipment and supplies (continuation) 
Material  Source Information 
Centrifuge tube Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
Nunc™, 15ml 
Heraeus Megafuge 16R 
Centrifuge 
Thermo Scientific, 
Thermo Fisher Scientific, 
Waltham, USA 
 
Incubator 
 
Memmert, Schwabach, 
Germany 
For cell cultures only 
37°C, no CO2 content 
Incubator Nalge Nunc International, 
Thermo Fisher Scientific, 
Waltham, USA 
For PAM and field virus 
propagation  
37°C, 0.5% CO2 
Incubator Nalge Nunc International, 
Thermo Fisher Scientific, 
Waltham, USA 
For intentions other than 
cell culture, PAM or field 
virus propagation,  
37°C, 5% CO2 
ELISA reader  TECAN Austria GmbH, 
Grödig, Austria 
Sunrise™ 
ELISpot reader AID Autoimmun 
Diagnostica GmbH, 
Straßberg, Germany 
AID iSpot FluoroSpot 
Reader System 
Intensilight C-HGFI Nikon, Tokyo, Japan Fluorescence microscope 
 
 
 
 
 
 
 
 
 
 
Annex  70 
 
Annex 2. IFN-γ ELISA test kits 
 
Annex 2.1: Components of the different IFN-γ-RA’s (for origin of components not 
included in a kit see annex 1) 
Testkit A B 
  
Self coating Self coating 
Microplates 
Included in testkit X X 
Pre-coated X X 
Wash buffer 
Included in testkit X X 
Composition 
PBS + 0.05% 
Tween20 
PBS + 0.05% 
Tween20 
Reagent diluent/ 
incubation buffer 
Included in testkit X X 
Composition 
PBS + 1% BSA 
(Reagent Diluent) 
PBS + 0.05% 
Tween20 +0.1% 
BSA     
(incubation buffer) 
Capture antibody 
 
Monoclonal 
mouse  anti-
porcine IFN-γ, 
lyophilized 
Mouse 
monoclonal 
antibody specific 
for porcine IFN-γ 
Standard 
 
Recombinant 
porcine IFN-γ, 
lyophilized 
Recombinant 
porcine IFN-γ, 
lyophilized 
Porcine IFN-γ Kit 
Control  
X X 
Detection 
antibody  
Biotinylated 
polyclonal goat 
anti-porcine IFN-
γ, lyophilized 
Biotinylated 
mouse 
monoclonal 
antibody specific 
for bovine IFN-γ 
(cross reaction 
with porcine IFN-
γ) 
Additional 
reagents  
NSG X 
Streptavidin-HRP 
 
√ √ 
Substrate 
Solution  
X X 
Stop Solution 
 
X X 
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Annex 2.2: Implementation of the different IFN-γ-RA’s (according to manufacturer’s 
instructions) 
 Kit A Kit B 
The day before 
implementation 
Plate Preparation: 
Capture Antibody, 
diluted to 2µg/ml in 
PBS, 100µl/well, 
incubation overnight at 
4-8°C 
Plate Preparation: 
Capture Antibody, 
diluted to 2µg/ml in 
PBS, 100µl/well, 
incubation overnight at 
4-8°C 
Day of implementation 
Washing: 3 times Washing: 2 times 
Blocking: 300µl 
Reagent Diluent/well 
1 hour 
Blocking: 200µl 
incubation buffer/well 
1 hour 
Washing: 3 times Washing: 5 times 
Standard and sample, 
diluted 1:2 in Reagent 
Diluent, 
100µl/well 
2 hours 
Standard and sample, 
diluted 1:2 in 
incubation buffer, 
100µl/well 
2 hours 
Washing: 3 times Washing: 5 times 
Detection Antibody, 
diluted to 400ng/ml in 
Reagent Diluent with 
2% heat inactivated 
normal goat serum 
(NGS), 
100µl/well 
2 hours 
Detection antibody, 
diluted to 500ng/ml in 
incubation buffer 
 
 
 
100µl/well 
1 hour 
Washing: 3 times Washing: 5 times 
Streptavidin-HRP, 
diluted 1:200, 
100µl/well 
20 minutes 
Streptavidin-HRP, 
Diluted 1:1000, 
100µl/well 
1 hour 
Washing: 3 times Washing: 5 times 
Substrate Solution, 
100µl/well 
20 minutes 
Substrate Solution, 
100µl/well 
10 minutes 
Stop Solution, 
100µl/well 
Stop Solution, 
100µl/well 
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Annex 3. Recipes for preparation of buffers 
 
Annex 3.1: Recipe for 1l of PBS + 0.05% Tween 20 (wash buffer, Kit A and B) 
100ml  PBS (10x) 
900ml  aqua distillata (aqua dist.) 
500µl   Tween® 20 (Merck Millipore) 
 
Annex 3.2: Recipe for 1l of PBS + 1% BSA (Reagent Diluent, Kit A) 
100ml  PBS (10x) 
900ml  aqua distillata (aqua dist.) 
10g   bovine serum albumin (BSA, Sigma-Aldrich®) 
 
Annex 3.3: Recipe for 1l of PBS + 0.05% Tween 20 + 0.1% BSA (incubation buffer, 
Kit B) 
100ml  PBS (10x) 
900ml  aqua distillata (aqua dist.) 
500µl   Tween® 20 (Merck Millipore) 
1g   bovine serum albumin (BSA, Sigma-Aldrich®) 
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Annex 4. IFN-γ-reactivity in stocks and evaluability of samples: Exclusion of samples 
from analysis by application of validation criteria. 
Status of 
stocks 
Samples (total) SC<0.4 PBS≥0.2 Percent of evaluable samples 
OD 
Non-
vaccinated/ 
non-infected 
9 - - 100% 
9 2 - 78% 
10 - - 100% 
Non-
vaccinated/ 
infected 
9 - 4 56% 
10 2 - 80% 
11 - - 100% 
 
 
 
 
US-
vaccinated 
11 - - 100% 
10 3 - 70% 
10 1 - 90% 
10 - 4 60% 
10 2 1 70% 
10 - 1 90% 
10 1 - 90% 
10 3 - 70% 
9 - - 100% 
10 - - 100% 
 
 
 
 
 
 
 
EU-
vaccinated 
10 1 2 70% 
10 - - 100% 
10 - - 100% 
10 - 2 80% 
5 - - 100% 
10 - - 100% 
10 - 1 90% 
10 1 1 80% 
10 - - 100% 
10 - - 100% 
10 - 1 90% 
10 1 - 90% 
7 - - 100% 
10 3 - 70% 
10 - - 100% 
 300 20 17 87,9% 
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A5: Correlation of results between antibody ELISA, SNT and IFN-γ ELISA. 
ELISA SNT IFN-γ % of total samples 
Positive (71.3%) 
Negative (9%) 
Negative 6.1 
US positive 0.4 
EU positive 2.1 
US/EU positive 0.4 
US positive (5.7%) 
Negative 4.9 
US positive 0 
EU positive 0 
US/EU positive 0.8 
EU positive (38.9%) 
Negative 24.6 
US positive 0 
EU positive 13.1 
US/EU positive 1.2 
US/EU positive 
(17.7%) 
Negative 7 
US positive 0.4 
EU positive 7.8 
US/EU positive 2.5 
Negative (28,7%) 
Negative (20.1%) 
Negative 16.8 
US positive 2.5 
EU positive 0.4 
US/EU positive 0.4 
US positive (2.8%) 
Negative 1.2 
US positive 1.6 
EU positive 0 
US/EU positive 0 
EU positive (3.7%) 
Negative 2.5 
US positive 0.4 
EU positive 0 
US/EU positive 0.8 
US/EU positive (2.1%) 
Negative 2.1 
US positive 0 
EU positive 0 
US/EU positive 0 
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